Banu Arun, MD

Peer-Reviewed Articles

1. Rinkenbaugh AL, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones SL, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, den Hollander P, Ravenberg EE, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans WF, Chang JT, Piwnica-Worms H. An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy. Cancer Res 85(21):4062-80, 2025. e-Pub 2025. PMID: 40801311.
2. Arun B, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, et al. Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 16(1):8237, 2025. e-Pub 2025. PMID: 40925936.
3. Loghavi S, Abdel-Salam H, Hammond D, Chien K, Patel KP, Arun BK, DiNardo CD. Unveiling the Origins of Pathogenic TP53 Variants in Clinical Context: A Molecular Tumor Board Case Discussion. JCO Precis Oncol 9:e2500636, 2025. e-Pub 2025. PMID: 40991881.
4. Dibble EH, Vaz SC, Arun B, Fowler AM, Geus-Oei LD, Hunt KN, Jain R, Rauch GM, Teshome M, Covington MF. Appropriate Use Criteria for Molecular Breast Imaging. J Nucl Med Technol jnmt.125.270865. doi: 10.2967/jnmt.125.270865, 2025. PMID: 40858505.
5. Huynh VD, Mouabbi J, Kuerer HM, Wanis KN, Abdel-Salam HM, Gutierrez AM, Johnson HM, Lucci A, Hunt KK, Arun BK. Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma. Ann Surg Oncol 32(8):5477-88, 2025. e-Pub 2025. PMID: 40314901.
6. Kizub D, Bluebond R, Green S, Duckworth J, Shanker S, Vara A, Arun B. Improving genetics equity: identifying women eligible for genetic care services using mammography clinics in underserved areas as screening hubs. Oncologist 30(7), 2025. e-Pub 2025. PMID: 40613751.
7. Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14):e173757, 2025. e-Pub 2025. PMID: 40460005.
8. Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer HM, Meas S, Sarli VN, Korkut A, White JB, Rauch GM, Tripathy D, Arun, BK, Barcenas CH, Yam C, Sethi H, Rodriguez AA, Liu MC, Moulder SL, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1), 2024. e-Pub 2024. PMID: 39148033.
9. McGuinness JE, Anderson GL, Mutasa S, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser ML, Goodman GE, Brown PH, Ha R, Crew KD. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr 8(4), 2024. e-Pub 2024. PMID: 38814817.
10. Arun BK, Wang W. Performance of LFSPRO TP53 germline carrier risk predictions compared to standard genetic counseling practice on prospectively collected probands (preprint). medRxiv, 2024. e-Pub 2024. PMID: 39040185.
11. Bundrant B, Gerstein Y, Arun B, DiNardo CD. Hematologic malignancies in Li-Fraumeni syndrome: A case report. Am J Med Genet A 194(7):e63573, 2024. e-Pub 2024. PMID: 38410872.
12. Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer, 2024. e-Pub 2024. PMID: 38985794.
13. Brown K, Ponton M, Davidson E, Arun B, Volk RJ, Shete S, Peterson SK, Makhnoon S. What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open-ended survey responses. Cancer, 2024. e-Pub 2024. PMID: 38843377.
14. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med 5(6):101595, 2024. e-Pub 2024. PMID: 38838676.
15. Nguyen NH, Dodd-Eaton EB, Corredor JL, Woodman-Ross J, Green S, Gutierrez AM, Arun BK, Wang W. Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol 42(18):2186-95, 2024. e-Pub 2024. PMID: 38569124.
16. Wanis KN, Kuerer HM, Sun SX, Hunt KK, Glencer AC, Teshome M, Lucci A, Weiser R, Johnson H, Smith BD, Gutierrez AM, Shaitelman SF, Arun BK. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open 7(6):e2418486, 2024. e-Pub 2024. PMID: 38916888.
17. Akkoc Mustafayev FN, Shukla MA, Lanier A, Milton DR, Gutierrez AM, Gruschkus SK, Lewis JE, Murthy RK, Arun BK. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer 130(9):1600-8, 2024. e-Pub 2024. PMID: 38100492.
18. Crew KD, Anderson GL, Arnold KB, Stieb AP, Amenta JN, Collins N, Law CW, Pruthi S, Sandoval-Leon A, Bertoni D, Grosse Perdekamp MT, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino D, Wisinski KB, DeYoung CA, Ross M, Floyd J, Kaster A, Vander Walde L, Saphner T, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Kukafka R. Making informed choices on incorporating chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials, 2024. e-Pub 2024. PMID: 38704119.
19. Ricker C, Arun B, Pirzadeh-Miller S, Stoffel EM, Messersmith H, Tung N. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights. JCO Oncol Pract, 2024. e-Pub 2024. PMID: 38759126.
20. Tung N, Ricker C, Messersmith H, Balmaña J, Domchek S, Stoffel EM, Almhanna K, Arun B, Chavarri-Guerra Y, Cohen SA, Cragun D, Crew KD, Hall MJ, Idos G, Lopez G, Pal T, Pirzadeh-Miller S, Pritchard C, Rana HQ, Swami U, Vidal GA. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol, 2024. e-Pub 2024. PMID: 38759122.
21. Ricker C, Arun B, Pirzadeh-Miller S, Stoffel EM, Messersmith H, Tung N. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights. JCO Oncol Pract, 2024. e-Pub 2024. PMID: 38759122.
22. Diéras V, Han HS, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Loirat D, Ratajczak C, Adamu H, Girardi V, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer 200(113580), 2024. e-Pub 2024. PMID: 38309017.
23. Bevers TB, Sardesai S, Ahrendt GM, Arun BK, Colditz GA, Fejerman L, Fisher C, Gandhi S, Gemignani ML, Goodwin HA, Gradishar WJ, Henderson K, Hendrix AA, Hwang S, Jacobs L, Jordan JA, King T, Kurian AW, Loftus LS, Master A, Merajver SD, Meszoely IM, Mukhtar R, Parker, CC, Pruthi S, Rahimi A, Seewaldt V, Shah PD, Shubeck S, Specht MC, Wallace A, Wilke LG, Yellala A, Yung, Bergman MA, Kumar R. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer Risk Reduction 2(2024), 2024. e-Pub 2024.
24. Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun BK, et al. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk. medRxiv (Reprint) 2024.02.29.24303243, 2024. e-Pub 2024. PMID: 38496424.
25. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. JCO Precis Oncol. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes 8(e2300124), 2024. e-Pub 2024. PMID: 38484209.
26. Baydogan S, Mohindroo C, Hasanov M, Montiel MF, Quesada P, Cazacu IM, Luzuriaga Chavez AA, Mork ME, Dong W, Feng L, You YN, Arun B, Vilar E, Brown P, Katz MHG, Chari ST, Maitra A, Tamm EP, Kim MP, Bhutani MS, McAllister F. New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study. Endosc Ultrasound 13(2):83-8, 2024. e-Pub 2024. PMID: 38947744.
27. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol, 2024. e-Pub 2024. PMID: 38484209.
28. Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
29. Nguyen NH, Dodd-Eaton EB, Peng G, Corredor JL, Jiao W, Woodman-Ross J, Arun BK, Wang W. LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations. JCO Clin Cancer Inform 8(e2300167), 2024. e-Pub 2024. PMID: 38346271.
30. Gracia B, Montes P, Gutierrez AM, Arun B, Karras GI. Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers. Cell Rep 43(2):113803, 2024. e-Pub 2024. PMID: 38368609.
31. Al Sukhun S, Koczwara B, Temin S, Arun BK. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A. JCO Glob Oncol 10(e2300411), 2024. e-Pub 2024. PMID: 38206289.
32. Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol 10(e2300285), 2024. e-Pub 2024. PMID: 38206277.
33. Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health 9(4):267-73, 2023. e-Pub 2023. PMID: 37795002.
34. Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A, Hutton ML, Karlan BY, Kassem N, Khan S, Khoury K, Kurian AW, Laronga C, Mak JS, Mansour J, McDonnell K, Menendez CS, Merajver SD, Norquist BS, Offit K, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Visvanathan K, Welborn J, Wick MJ, Wood M, Yurgelun MB, Dwyer MA, Darlow SD. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw 21(10):1000-10, 2023. e-Pub 2023. PMID: 37856201.
35. Nguyen NH, Dodd-Eaton EB, Corredor JL, Woodman-Ross J, Green S, Hernandez ND, Gutierrez Barrera AM, Arun BK, Wang W. Validating risk prediction models for multiple primaries and competing cancer outcomes in families with Li-Fraumeni syndrome using clinically ascertained data at a single institute. medRxiv [Preprint] 2023.08.31.23294849, 2023. e-Pub 2023. PMID: 37693464.
36. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat, 2023. e-Pub 2023. PMID: 37751078.
37. Stolarova L, Kleiblova P, Zemankova P, Stastna B, Janatova M, Soukupova J, Achatz MI, Ambrosone C, Apostolou P, Arun BK, Auer P, Barnard M, Bertelsen B, Japan B, Blok MJ, Boddicker N, Brunet J, Burnside ES, Calvello M, Campbell I, Chan SH, Chen F, Chiang JB, Coppa A, Cortesi L, Crujeiras-González A, CZECANCA C, De Leeneer K, De Putter R, DePersia A, Devereux L, Domchek S, Efremidis A, Engel C, Ernst C, Evans DGR, Feliubadaló L, Fostira F, Fuentes-Ríos O, Gómez-García EB, González S, Haiman C, Hansen TVO, Hauke J, Hodge J, Hu C, Huang H, Ishak NDB, Iwasaki Y, Konstantopoulou I, Kraft P, Lacey J, Lázaro C, Li N, Lim WK, Lindstrom S, Lori A, Martinez E, Martins A, Matsuda K, Matullo G, McInerny S, Michailidou K, Montagna M, Monteiro ANA, Mori L, Nathanson K, Neuhausen SL, Nevanlinna H, Olson JE, Palmer J, Pasini B, Patel A, Piane M, Poppe B, Radice P, Renieri A, Resta N, Richardson ME, Rosseel T, Ruddy KJ, Santamariña M, Dos Santos ES, Teras L, Toland AE, Trentham-Dietz A, Vachon CM, Volk AE, Weber-Lassalle N, Weitzel JN, Wiesmuller L, Winham S, Yadav S, Yannoukakos D, Yao S, Zampiga V, Zethoven M, Zhang ZW, Zima T, Spurdle AB, Vega A, Rossing M, Del Valle J, De Nicolo A, Hahnen E, Claes KBM, Ngeow J, Momozawa Y, James PA, Couch FJ, Macurek L, Kleibl Z. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk. Clin Cancer Res 26(16):3037-50, 2023. e-Pub 2023. PMID: 37449874.
38. Nguyen NH, Dodd-Eaton EB, Peng G, Corredor JL, Jiao W, Woodman-Ross J, Arun BK, Wang W. LFSPROShiny: an interactive R/Shiny app for prediction and visualization of cancer risks in families with deleterious germline TP53 mutations. medRxiv [Preprint] 2023.08.11.23293956, 2023. e-Pub 2023. PMID: 37645796.
39. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422. doi: 10.1177/17588359231189422. eCollection 2, 2023. e-Pub 2023. PMID: 37547448.
40. Makhnoon S, Davidson E, Shirts B, Arun B, Shete S. Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey. JCO Precis Oncol:e2300079. doi: 10.1200/PO.23.00079, 2023. e-Pub 2023.
41. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13):3275, 2023. e-Pub 2023. PMID: 37444385.
42. Drula R, Pardini B, Fu X, De Los Santos MC, Jurj A, Pang L, El-Daly SM, Fabris L, Knutsen E, Dragomir MP, Bayraktar R, Li Y, Chen M, Del Vecchio F, Berland L, Dae J, Fan D, Shimizu M, Tran AM, Barzi M, Pioppini C, Gutierrez AM, Ivan C, Meas S, Hall CS, Alahari SK, Berindan-Neagoe I, Fabbri M, Lucci A, Arun B, Anfossi S, Calin GA. 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer. Proc Natl Acad Sci U S A 120(23), 2023. e-Pub 2023. PMID: 37252969.
43. Murphy BL, Arun BK. ASO Author Reflections: Other Cancers in Patients with Breast Cancer Who Undergo Germline Testing. Ann Surg Oncol 30(5):2914-5, 2023. e-Pub 2023. PMID: 36705815.
44. Bednar EM, Chen M, Jr WM, Eppolito AL, Klein MH, Teed K, Hodge B, Hunter J, Chao HG, Davis D, Serchion W, Yobbi C, Krukenberg R, Jenkinson SB, Moore JJ, Garcia C, Gonzalez F, Murray T, Nielsen LD, Ho B, Haas M, Greenzweig SB, Anderson A, Johnson C, Morman NA, Bowdish E, Wise E, Cooper JN, Russ PK, Tondo-Steele K, de Gracia BF, Levin B, Mattie K, Zarnawski K, Kalasinski M, Stone J, O'Brien C, Bream A, Kennedy AM, Paul RA, Bilbao M, Romero M, Carr RL, Siettmann JM, Vercruyssen AK, Leon K, Arun BK, Grainger AV, Warshal DP, Bowman E, Goedde TA, Halaharvi D, Rath K, Grana G, Mina L, Lu KH. Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems. Gynecol Oncol(172):106-14, 2023. e-Pub 2023. PMID: 37004303.
45. Muranen TA, Morra A, Khan S, Barnes DR, Bolla MK, Dennis J, Keeman R, Leslie G, Parsons MT, Wang Q, Ahearn TU, Aittomäki K, Andrulis IL, Arun BK, Behrens S, Bialkowska K, Bojesen SE, Camp NJ, Chang-Claude J, Czene K, Devilee P, investigators H, Domchek SM, Dunning AM, Engel C, Evans DG, Gago-Dominguez M, García-Closas M, Gerdes AM, Glendon G, Guénel P, Hahnen E, Hamann U, Hanson H, Hooning MJ, Hoppe R, Izatt L, Jakubowska A, James PA, Kristensen VN, Lalloo F, Lindeman GJ, Mannermaa A, Margolin S, Neuhausen SL, Newman WG, Peterlongo P, Phillips KA, Pujana MA, Rantala J, Rønlund K, Saloustros E, Schmutzler RK, Schneeweiss A, Singer CF, Suvanto M, Tan YY, Teixeira MR, Thomassen M, Tischkowitz M, Tripathi V, Wappenschmidt B, Zhao E, Easton DF, Antoniou AC, Chenevix-Trench G, Pharoah PDP, Schmidt MK, Blomqvist C, Nevanlinna H. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. NPJ Breast Cancer 9(1):37, 2023. e-Pub 2023. PMID: 37173335.
46. Abuhadra N, Sun R, Jr BR, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs, 2023. e-Pub 2023. PMID: 37043123.
47. Saha S, Sriram Prasath S, Arun B, Kalita SJ, Elavarasan N, Guha Adhya D, Sarkar A, Arunsingh M, Chakraborty S, Mallick I. ICON-P - A double-blind evaluation of quality improvements with individualized CONstraints from low-cost knowledge-based radiation therapy planning in prostate cancer. Tech Innov Patient Support Radiat Oncol, 2023. e-Pub 2023. PMID: 37274093.
48. Murphy BL, Yi M, Barrera AG, Tripathy D, Hunt KK, Arun BK. ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. Ann Surg Oncol, 2023. e-Pub 2023. PMID: 36210399.
49. Murphy BL, Yi M, Gutierrez Barrera AM, Tripathy D, Hunt KK, Arun BK. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. Ann Surg Oncol 30(3):1663-8, 2023. e-Pub 2023. PMID: 36094691.
50. Makhnoon S, Levin B, Ensinger M, Mattie K, Volk RJ, Zhao Z, Mendoza T, Shete S, Samiian L, Grana G, Grainger A, Arun B, Shirts BH, Peterson SK. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. Cancer Med 12(3):2875-84, 2023. e-Pub 2023. PMID: 36426404.
51. Makhnoon S, Gutierrez Barrera AM, Bassett R, Afrough A, Bedrosian I, Arun BK. Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences. Breast J, 2022. e-Pub 2022. PMID: 36685664.
52. Makhnoon S, Levin B, Ensinger M, Mattie K, Volk RJ, Zhao Z, Mendoza T, Shete S, Samiian L, Grana G, Grainger A, Arun B, Shirts BH, Peterson SK. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. Cancer Med, 2022. e-Pub 2022. PMID: 36426404.
53. Roberts G, Benusiglio PR, Bisseling T, Coit D, Davis JL, Grimes S, Guise TA, Hardwick R, Harris K, Mansfield PF, Rossaak J, Schreiber KC, Stanich PP, Strong VE, Kaurah P, Group LS. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer 25(6):1094-1104, 2022. e-Pub 2022. PMID: 35831514.
54. Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, Arun B. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat 196(1):143-52, 2022. e-Pub 2022. PMID: 36006499.
55. Murphy BL, Yi M, Barrera AG, Tripathy D, Hunt KK, Arun BK. ASO Visual Abstract: Other primary malignancies in patients with breast cancer who undergo germline panel testing. Ann Surg Oncol, 2022. e-Pub 2022. PMID: 36210399.
56. Makhnoon S, Chen M, Levin B, Ensinger M, Mattie KD, Grana G, Shete S, Arun BK, Peterson SK. Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes. Cancer 128(20):3709-17, 2022. e-Pub 2022. PMID: 35996941.
57. Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, Robinson BA, Mace PD, Aittomäki K, Andrulis IL, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Belhadj S, Berger L, Blok MJ, Boonen SE, Borde J, Bradbury AR, Brunet J, Buys SS, Caligo MA, Campbell I, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Collonge-Rame MA, Cook J, Cosgrove C, Couch FJ, Daly MB, Dandiker S, Davidson R, de la Hoya M, de Putter R, Delnatte C, Dhawan M, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Easton DF, Ehrencrona H, Engel C, Evans DG, Faust U, Feliubadaló L, Fostira F, Friedman E, Frone M, Frost D, Garber J, Gayther SA, Gehrig A, Gesta P, Godwin AK, Goldgar DE, Greene MH, Hahnen E, Hake CR, Hamann U, Hansen TVO, Hauke J, Hentschel J, Herold N, Honisch E, Hulick PJ, Imyanitov EN, Investigators S, Investigators K, Investigators H, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kemp Z, Kirk J, Konstantopoulou I, Koudijs M, Kwong A, Laitman Y, Lalloo F, Lasset C, Lautrup C, Lazaro C, Legrand C, Leslie G, Lesueur F, Mai PL, Manoukian S, Mari V, Martens JWM, McGuffog L, Mebirouk N, Meindl A, Miller A, Montagna M, Moserle L, Mouret-Fourme E, Musgrave H, Nambot S, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nguyen-Dumont T, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Ott CE, Park SK, Parsons MT, Pedersen IS, Peixoto A, Perez-Segura P, Peterlongo P, Pocza T, Radice P, Ramser J, Rantala J, Rodriguez GC, Rønlund K, Rosenberg EH, Rossing M, Schmutzler RK, Shah PD, Sharif S, Sharma P, Side LE, Simard J, Singer CF, Snape K, Steinemann D, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Trainer AH, Tripathi V, Tung N, van Engelen K, van Rensburg EJ, Vega A, Viel A, Walker L, Weitzel JN, Wevers MR, Chenevix-Trench G, Spurdle AB, Antoniou AC, Walker LC. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol 5(1):1061, 2022. e-Pub 2022. PMID: 36203093.
58. Murphy BL, Yi M, Gutierrez Barrera AM, Tripathy D, Hunt KK, Arun BK. Other primary malignancies in patients with breast cancer who undergo germline panel testing. Ann Surg Oncol, 2022. e-Pub 2022. PMID: 36094691.
59. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell 5(876100), 2022. e-Pub 2022. PMID: 36034598.
60. McDonnell GA, Peshkin BN, DeMarco TA, Peterson SK, Arun BK, Miesfeldt S, O'Neill SC, Schneider K, Garber J, Isaacs C, Luta G, Tercyak KP. Long-term adaptation among adolescent and young adult children to familial cancer risk. Pediatrics 150(2), 2022. e-Pub 2022. PMID: 35859209.
61. Kara G, Arun B, Calin GA, Ozpolat B. miRacle of microRNA-Driven Cancer Nanotherapeutics. Cancers (Basel) 14(15):3818, 2022. e-Pub 2022. PMID: 35954481.
62. Makhnoon S, Arun B, Bedrosian I. Helping patients understand and cope with BRCA mutations. Curr Oncol Rep 24(6):733-40, 2022. e-Pub 2022. PMID: 35303253.
63. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Parra Cuentas ER, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35736816.
64. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. e-Pub 2022. PMID: 35538088.
65. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35507014.
66. Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. NPJ Breast Cancer 8(1):46, 2022. e-Pub 2022. PMID: 35393462.
67. Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L, working group SA, Arun B, Herold N, Versmold B, Schmutzler RK, GC-HBOC, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE, CARRIERS, Groups A, Stoppa-Lyonnet D, Andrieu N. First international workshop of the ATM and cancer risk group (4-5 December 2019). Fam Cance 21(2):211-27, 2022. e-Pub 2022. PMID: 34125377.
68. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Collaborators GS, Collaborators GS, Collaborators E, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Group OS, Group A, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Investigators K, Investigators H, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet, 2022. e-Pub 2022. PMID: 35314806.
69. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Collaborators GS, Collaborators GS, Collaborators E, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Group OS, Group A, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Investigators K, Investigators H, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 30(3):349-62, 2022. e-Pub 2022. PMID: 35027648.
70. an HS, Arun BK, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bach BA, Kundu MG, Khandelwal N, Feng D, Bhattacharya S, Maag D, Ratajczak CK, Diéras V. Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Ann Oncol 33(3):299-309, 2022. e-Pub 2022. PMID: 34861374.
71. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Jr BR, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5):1323, 2022. e-Pub 2022. PMID: 35267631.
72. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing. Int J Radiat Oncol Biol Phys 112(2):437-44, 2022. e-Pub 2022. PMID: 34582940.
73. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes after breast radiation therapy in a diverse patient cohort with a germline BRCA1/2 mutation. Int J Radiat Oncol Biol Phys 112(2):426-36, 2022. e-Pub 2022. PMID: 34610390.
74. Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK. Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. Contemp Clin Trials 113:106662, 2022. e-Pub 2022. PMID: 34971795.
75. Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med, 2022. e-Pub 2022. PMID: 35128817.
76. Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer 128(1):94-102, 2022. e-Pub 2022. PMID: 34424535.
77. Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/ 2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol, 2021. e-Pub 2021. PMID: 34917174.
78. Siettmann JM, Arun B, Gasparini J, Mina LA. Personalized breast cancer risk assessment: incorporation of genetic and high-risk factorson breast cancer risk and management. Chirurgia (Bucur) 116(5 Suppl):S22-S34, 2021. e-Pub 2021. PMID: 34967308.
79. Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam KM, Arun B, Ibrahim NK. Molecular spectra and frequency patterns of somatic mutations in arab women with breast cancer. Oncologist 26(11):e2086-e2089, 2021. e-Pub 2021. PMID: 34327780.
80. Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam KM, Arun B, Ibrahim NK. Molecular spectra and fequency patterns of somatic mutations in arab women with breast cancer. Oncologist 26(11):e2086-e2089, 2021. e-Pub 2021. PMID: 34327780.
81. Puhalla SL, Diéras V, Arun BK, Kaufman B, Wildiers H, Han HS, Ayoub JP, Stearns V, Yuan Y, Helsten T, Riley-Gillis B, Murphy E, Kundu MG, Wu M, Maag D, Ratajczak CK, Ramathal CY, Friedlander M. Relevance of platinum-free interval and brca reversion mutations for veliparib monotherapy after progression on carboplatin/paclitaxel for g brca advanced breast cancer (BROCADE3 Crossover). Clin Cancer Res 27(18):4983-93, 2021. e-Pub 2021. PMID: 34131001.
82. Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK. Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer 27(19):3605-13, 2021. e-Pub 2021. PMID: 34157779.
83. Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V. Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer 154:35-45, 2021. e-Pub 2021. PMID: 34243076.
84. Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Collée JM, Couch FJ, Daly MB, Dennis J, Dhawan M, Domchek SM, Eeles R, Engel C, Evans DG, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Gayther SA, Gerdes AM, Godwin AK, Goldgar DE, Hahnen E, Hake CR, Hamann U, Hogervorst FBL, Hooning MJ, Hopper JL, Hulick PJ, Imyanitov EN, Investigators O, Investigators H, Investigators K, Isaacs C, Izatt L, Jakubowska A, James PA, Janavicius R, Jensen UB, Jiao Y, John EM, Joseph V, Karlan BY, Kets CM, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud JT, Lubiński J, Manoukian S, McGuffog L, Miller A, Gomes DM, Montagna M, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Olah E, Olopade OI, Park SK, Parsons MT, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch HA, Schmutzler RK, Sharma P, Simard J, Singer CF, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Wappenschmidt B, Devilee P, van Asperen CJ, Bernstein JL, Offit K, Easton DF, Rookus MA, Chenevix-Trench G, Antoniou AC, Robson M, Schmidt MK. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med 23(9):1726-37, 2021. e-Pub 2021. PMID: 34113011.
85. Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg 274(2):e150-e159, 2021. e-Pub 2021. PMID: 31436549.
86. Elghazaly H, Aref AT, Anderson BO, Arun B, Yip CH, Abdelaziz H, Ghosn M, Al-Foheidi M, Cardenosa G, Leung JWT, Gado N, Balch CM, Sabry M, Ezz Elarab L, Giuliano AE, El-Zawahry HM, Abdel Karim K, Nasr A, Maki H, Chung H, Saadeddin A, Abdelwahab MM, Al Tahan FM, Chalabi N, Frolova M, Kamal RM, Shehata MA, Bahie Eldin N, Elghazawy H. The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA region. Int J Cancer 149(3):505-13, 2021. e-Pub 2021. PMID: 33559295.
87. Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK. Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication. J Community Genet 12(3):439-47, 2021. e-Pub 2021. PMID: 33481188.
88. Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK. Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: opportunity for prompting family communication. J Community Genet 12(3):439-47, 2021. e-Pub 2021. PMID: 33481188.
89. Rajanna M, Bharathi B, Shivakumar BR, Deepak M, Prashanth D, Prabakaran D, Vijayabhaskar T, Arun B. Immunomodulatory effects of Andrographis paniculata extract in healthy adults - An open-label study. J Ayurveda Integr Med 12(3):529-34, 2021. e-Pub 2021. PMID: 34376353.
90. Makhnoon S, Corredor J, Arun B, Bell D, Yarbrough A, Livingston JA, Peterson SK, Roth M. Impact of a genetic evaluation initiative to increase access to genetic services for adolescent and young adults at a tertiary cancer hospital. J Adolesc Young Adult Oncol 10(3):296-302, 2021. e-Pub 2021. PMID: 32830989.
91. Burke S, Mork M, Qualmann K, Woodson A, Jin Ha M, Arun B, Kaulfus M. J Genet Coun. Genetic counselor approaches to BRCA1/2 direct-to-consumer genetic testing results 30(3):803-12, 2021. e-Pub 2021. PMID: 33550665.
92. Klugman S, Schnabel F, Alim I, Loke J, Arun B, Chun Kim J, Ostrer H. Health care professionals' attitudes toward cancer gene panel testing. Breast J 27(5):499-500, 2021. e-Pub 2021. PMID: 33677830.
93. Ratcliff CG, Zepeda SG, Hall MH, Tullos EA, Fowler S, Chaoul A, Spelman A, Arun B, Cohen L. Patient characteristics associated with sleep disturbance in breast cancer survivors. Support Care Cancer 29(5):2601-11, 2021. e-Pub 2021. PMID: 32964261.
94. Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Breast-gynaecological & immuno-oncology international cancer conference (BGICC) consensus and recommendations for the management of triple-negative breast cancer. Cancers (Basel) 13(9):2262, 2021. e-Pub 2021. PMID: 34066769.
95. Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collaborators GS, Collaborators E, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Investigators K, Investigators H, Investigators A, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Re. Author correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun 12(1):2986, 2021. e-Pub 2021. PMID: 33990587.
96. Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ. Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol 50(3):303-7, 2021. e-Pub 2021. PMID: 32033821.
97. Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, BK <, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting replicative stress and dna repair by combining parp and wee1 kinase inhibitors is synergistic in triple negative breast cancers with cyclin e or brca1 alteration. Cancers (Basel) 13(7):1656, 2021. e-Pub 2021. PMID: 33916118.
98. Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani A, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-8, 2021. e-Pub 2021. PMID: 33762732.
99. Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the decision to undergo contralateral prophylactic mastectomy among women with unilateral breast cancer. Cancers (Basel) 13(9):2050, 2021. e-Pub 2021. PMID: 33922702.
100. Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer 146:30-47, 2021. e-Pub 2021. PMID: 33578357.
101. Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collaborators GS, Collaborators E, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Investigators K, Investigators H, Investigators A, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Re. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun 12(1):1078, 2021. e-Pub 2021. PMID: 33597508.
102. Layman RM, Arun B. PARP inhibitors in triple-negative breast cancer including those with brca mutations. Cancer J 27(1):67-5, 2021. e-Pub 2021. PMID: 33475295.
103. Layman RM, Arun B. PARP inhibitors in triple-negative breast cancer including those with BRCA mutations. Cancer J 27(1):67-75, 2021. e-Pub 2021. PMID: 33475295.
104. Shen X, Wang R, Kim MJ, Hu Q, Hsu CC, Yao J, Klages-Mundt N, Tian Y, Lynn E, Brewer TF, Zhang Y, Arun B, Gan B, Andreeff M, Takeda S, Chen J, Park JI, Shi X, Chang CJ, Jung SY, Qin J, Li L. A surge of DNA damage links transcriptional reprogramming and hematopoietic deficit in fanconi anemia. Mol Cell 80(6):1013-1024.e6, 2020. e-Pub 2020. PMID: 33338401.
105. Basen-Engquist KM, Raber M, Carmack CL, Arun B, Brewster AM, Fingeret M, Schembre SM, Harrison C, Perkins HY, Li Y, Song J, Chen M, Murray JL. Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. Support Care Cancer 28(12):5821-5832, 2020. e-Pub 2020. PMID: 32249355.
106. Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Ann Surg Oncol 27(12):4613-21, 2020. e-Pub 2020. PMID: 32720048.
107. Makhnoon S, Mork M, Arun B, Volk RJ, Peterson SK. Perceptions of provider's epistemic authority in response to variant of uncertain significance-related recommendations. J Genet Couns 8:10.1002/jgc4.1337, 2020. e-Pub 2020. PMID: 33090616.
108. Scoggins ME, Arun BK, Candelaria RP, Dryden MJ, Wei W, Son JB, Ma J, Dogan BE. Should abbreviated breast MRI be compliant with American College of Radiology requirements for MRI accreditation?. Magn Reson Imaging 72:87-94, 2020. e-Pub 2020. PMID: 32622851.
109. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269-82, 2020. e-Pub 2020. PMID: 32861273.
110. Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med 22(10):1653-1666, 2020. e-Pub 2020. PMID: 32665703.
111. Bayraktar S, Baghaki S, Wu J, Liu DD, Gutierrez-Barrera AM, Bevers TB, Valero V, Sneige N, Arun BK. Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila) 13(9):795-802, 2020. e-Pub 2020. PMID: 32513785.
112. Damodaran S, Sember QC, Arun BK. Clinical implications of breast cancer tumor genomic testing. Breast J 26(8):1565-71, 2020. e-Pub 2020. PMID: 32696498.
113. Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J 26(8):1572-1582, 2020. e-Pub 2020. PMID: 32497289.
114. Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol 44(5):442-468, 2020. e-Pub 2020. PMID: 32115800.
115. Corredor J, Woodson AH, Gutierrez Barrera A, Arun B. Multigene panel testing results in patients with multiple breast cancer primaries. Breast J 26(7):1337-1342, 2020. e-Pub 2020. PMID: 31999039.
116. Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. J Natl Cancer Inst 112(6):607-16, 2020. e-Pub 2020. PMID: 31503278.
117. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet 52(6):572-581, 2020. e-Pub 2020. PMID: 32424353.
118. Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol 38(14):1539-1548, 2020. e-Pub 2020. PMID: 32097092.
119. Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr eCollection(20;4(2):pkaa002):pkaa002, 2020. e-Pub 2020. PMID: 32211581.
120. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38(5):388-394, 2020. e-Pub 2020. PMID: 31461380.
121. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Marjaneh MM, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet 52(1):56-73, 2020. e-Pub 2020. PMID: 31911677.
122. Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, Lu KH, Basen-Engquist K. Diet, weight management, physical activity and ovarian & breast cancer risk in women with BRCA1/2 pathogenic germline gene variants: systematic review. Hered Cancer Clin Pract eCollection(7;18:5):5, 2020. e-Pub 2020. PMID: 32165993.
123. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, MGEM A, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Enden ATJM HVD, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol 76(6):831-42, 2019. e-Pub 2019. PMID: 31537406.
124. Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA. The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys 105(4):698-712, 2019. e-Pub 2019. PMID: 31381960.
125. Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM, Investigators A, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, et al. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer 1(5):38, 2019. e-Pub 2019. PMID: 31700994.
126. Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond) 14(17):2315-2338, 2019. e-Pub 2019. PMID: 31432749.
127. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, et al. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun 10(1):4386, 2019. e-Pub 2019. PMID: 31548585.
128. Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat 176(3):545-556, 2019. e-Pub 2019. PMID: 31054033.
129. Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, BK <, Risk Assessment ISOC, Management. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J 25(4):575-577, 2019. e-Pub 2019. PMID: 31280501.
130. Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila) 12(7):481-490, 2019. e-Pub 2019. PMID: 31138522.
131. Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, MGEM A, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer 21(2):180-92, 2019. e-Pub 2019. PMID: 31213659.
132. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank M, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, MGEM A, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Á I, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC, Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D, Collaborators GS, HEBON, EMBRACE, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst 111(4):350-64, 2019. e-Pub 2019. PMID: 30312457.
133. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldés T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL, Collaborators E, Collaborators GS, Collaborators GS, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Dennis J, Devilee P, Diez O, Dörk T, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN, Investigators A, Investigators H, Investigators B, Isaacs C, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko YD, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leslie G, Lester J, Lesueur F, Lindström S, Long J, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Margolin S, Maurer T, Mavroudis D, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Ra. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun 10(1):1741, 2019. e-Pub 2019. PMID: 30988301.
134. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine D, et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun 10(1):431, 2019. e-Pub 2019. PMID: 30683880.
135. Cohen SA, Bradbury A, Henderson V, Hoskins K, Bednar E, Arun BK. Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. Am Soc Clin Oncol Educ Book 39:e34-e44, 2019. e-Pub 2019. PMID: 31099680.
136. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol 3:PO.18.00143, 2019. e-Pub 2019. PMID: 31517177.
137. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Jr BR, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
138. Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J Clin Oncol 36(31):3134-3143, 2018. e-Pub 2018. PMID: 30240327.
139. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjørge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell IG, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, DeFazio A, Dennis J, Díez O, Domchek SM, Dork T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Cilius Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Velez Edwards D, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Res 78(18):5419-5430, 2018. e-Pub 2018. PMID: 30054336.
140. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol 4(9):1207-13, 2018. e-Pub 2018. PMID: 29879283.
141. Abulkhair O, Al Balwi M, Makram O, Alsubaie L, Faris M, Shehata H, Hashim A, Arun B, Saadeddin A, Ibrahim E. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer. J Glob Oncol 4:1-9, 2018. e-Pub 2018. PMID: 30199306.
142. Clifton K, Gutierrez-Barrera A, Ma J, Jr BR, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat 170(1):101-9, 2018. e-Pub 2018. PMID: 29470805.
143. Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat 170(2):415-23, 2018. e-Pub 2018. PMID: 29574637.
144. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
145. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-26, 2018. e-Pub 2018. PMID: 29733510.
146. Bednar EM, Jr WM, Baker E, Muse KI, Oakley HD, Krukenberg RC, Dresbold CS, Jenkinson SB, Eppolito AL, Teed KB, Klein MH, Morman NA, Bowdish EC, Russ P, Wise EE, Cooper JN, Method MW, Henson JW, Grainger AV, Arun BK, Lu KH. Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings. J Genet Couns. e-Pub 2018. PMID: 29770910.
147. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B, EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A, Collaborators GS, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J, HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Nathanson KL. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39(5):593-620, 2018. e-Pub 2018. PMID: 29446198.
148. Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw 16(5):518-24, 2018. e-Pub 2018. PMID: 29752326.
149. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
150. Webster RD, Ross JL, Arun BK. The changing landscape of hereditary cancer genetic testing. Cancer 124(4):664-6, 2018. e-Pub 2018. PMID: 29266190.
151. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK. BRCA mutations in women with inflammatory breast cancer. Cancer 124(3):466-474, 2018. e-Pub 2018. PMID: 29044548.
152. Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer 18(1):152, 2018. e-Pub 2018. PMID: 29409476.
153. Arun BK, Gutierrez Barrera AM, Ueno NT. Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer 124(4):866, 2018. e-Pub 2018. PMID: 29266209.
154. Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, Li Y, Cohen L. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer Cytopathol 124(1):36-45, 2018. e-Pub 2018. PMID: 28940301.
155. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. e-Pub 2017. PMID: 29238749.
156. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL, Collaborators N, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Easton DF. Association analysis identifies 65 new breast cancer risk loci. Nature 551(7678):92-94, 2017. e-Pub 2017. PMID: 29059683.
157. Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med 6(11):2515-2522, 2017. e-Pub 2017. PMID: 29024537.
158. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila) 10(11):641-650, 2017. e-Pub 2017. PMID: 28877935.
159. Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H, Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23(15):4066-4076, 2017. e-Pub 2017. PMID: 28356425.
160. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun BK, Wang LE. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-9, 2017. e-Pub 2017. PMID: 20033770.
161. Milbury K, Kavanagh A, Meng Z, Chen Z, Chandwani KD, Garcia K, Perkins GH, McQuade J, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer 25(7):2103-210, 2017. e-Pub 2017. PMID: 28233122.
162. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton JK, Arun B, Hortobagyi GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711-3720, 2017. e-Pub 2017. PMID: 28167507.
163. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 9(7):493-511, 2017. e-Pub 2017. PMID: 28717401.
164. Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M. Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw 15(6):797-803, 2017. e-Pub 2017. PMID: 28596260.
165. Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 22(6):655-666, 2017. e-Pub 2017. PMID: 28469042.
166. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
167. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, group AS, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Å B, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, Study E, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, Collaborators GS, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J, Study H, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Pharoah PDP. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 49(5):680-691, 2017. e-Pub 2017. PMID: 28346442.
168. Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJ. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther 16(1):3-20, 2017. e-Pub 2017. PMID: 27903842.
169. Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B, EMBRACE, Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA, Collaborators GS, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL, HEBON, Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY, Investigators K, Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B, Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Sønderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR, Teulé A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, Simard J. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161(1):117-134, 2017. e-Pub 2017. PMID: 27796716.
170. Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE, Felicio PS, Souza CP, Mendes DR, Volc S, Berardinelli GN, Grasel RS, Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM, Palmero EI. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 7(49):80465-80481, 2016. e-Pub 2016. PMID: 27741520.
171. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S, EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV, HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res 18(1):112, 2016. e-Pub 2016. PMID: 27836010.
172. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB, Collaborators GS, Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S, EMBRACE, Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S, Breast H, Group Netherlands OCR, Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN, Investigators K, Study Group AOC, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Gayther SA. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675, 2016. e-Pub 2016. PMID: 27601076.
173. Lu Q, You J, Kavanagh A, Warmoth K, Meng Z, Chen Z, Chandwani KD, Perkins GH, McQuade JL, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer 24(9):3775-82, 2016. e-Pub 2016. PMID: 27048455.
174. Ratcliff CG, Milbury K, Chandwani KD, Chaoul A, Perkins G, Nagarathna R, Haddad R, Nagendra HR, Raghuram NV, Spelman A, Arun B, Wei Q, Cohen L. Examining Mediators and Moderators of Yoga for Women With Breast Cancer Undergoing Radiotherapy. Integr Cancer Ther 15(3):250-62, 2016. e-Pub 2016. PMID: 26867802.
175. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 159(1):201, 2016. e-Pub 2016. PMID: 27464794.
176. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Ad P, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One 11(7):e0158801, 2016. e-Pub 2016. PMID: 27463617.
177. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
178. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist 21(7):869-74, 2016. e-Pub 2016. PMID: 27306910.
179. Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319-27, 2016. e-Pub 2016. PMID: 27117159.
180. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Broeks A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldes T, Campbell I, Carpenter J, Chang-Claude J, Choi JY, Claes KB, Clarke C, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, De Leeneer K, Devilee P, Diez O, Domchek SM, Doody M, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Dworniczak B, Egan K, Eilber U, Einbeigi Z, Ejlertsen B, Ellis S, Frost D, Lalloo F, EMBRACE, Fasching PA, Figueroa J, Flyger H, Friedlander M, Friedman E, Gambino G, Gao YT, Garber J, García-Closas M, Gehrig A, Damiola F, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Study Collaborators BOG, Giles GG, Godwin AK, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Haiman CA, Hallberg E, Hamann U, Hansen TV, Hart S, Hartikainen JM, Hartman M, Hassan N, Healey S, Hogervorst FB, Verhoef S, HEBON, Hendricks CB, Hillemanns P, Hollestelle A, Hulick PJ, Hunter DJ, Imyanitov EN, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Joly Beauparlant C, Jones M, Kabisch M, Kang D, Karlan BY, Kauppila S, Kerin MJ, Khan S, Khusnutdinova E, Knight JA, Konstantopoulou I, Kraft P, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Le Marchand L, Lee CN, Lee MH, Lester J, Li J, Liljegren A, Lindblom A, Lophatananon A, Lubinski J, Mai PL, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McGuffog L, Meindl A, Menegaux F, Montagna M, Muir K, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Newcomb PA, Nord S, Nussbaum RL, Offit K, Olah E, Olopade OI, Olswold C, Osorio A, Papi L, Zheng W. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18(1):64, 2016. e-Pub 2016. PMID: 27459855.
181. Association Consortium OC, Association Consortium BC, of BRCA ACOM, BRCA, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141(2):386-401, 2016. e-Pub 2016. PMID: 25940428.
182. Acharya S, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun B, Seewaldt V, Yu D. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. Am J Cancer Res 6(5):981-95, 2016. e-Pub 2016. PMID: 27293993.
183. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
184. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JI, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dörk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins B, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, Arun BK, Edwards SL. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet 48(4):374-86, 2016. e-Pub 2016. PMID: 26928228.
185. Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK. Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. Front Genet 7:71, 2016. e-Pub 2016. PMID: 27200080.
186. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Antoniou AC. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun(7):11375, 2016. e-Pub 2016. PMID: 27117709.
187. Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G. A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat 155(2):375-83, 2016. e-Pub 2016. PMID: 26786860.
188. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. e-Pub 2016. PMID: 26706041.
189. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. e-Pub 2016. PMID: 26706041.
190. Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, Richards-Kortum R, Jia W, Seewaldt VL, Yu D. Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer. Cancer Res 75(22):4863-75, 2015. e-Pub 2015. PMID: 26383165.
191. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM, Syngal S, Wollins DS, Lindor NM. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33(31):3660-7, 2015. e-Pub 2015. PMID: 26324357.
192. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 121(19):3422-7, 2015. e-Pub 2015. PMID: 26280679.
193. Litton JK, Lee JH, Arun BK. Reply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer 121(17):3047, 2015. e-Pub 2015. PMID: 26018033.
194. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological features of non-neoplastic breast parenchyma do not predict BRCA mutation status of patients with invasive breast cancer. Biomark Cancer 7(7):39-49, 2015. e-Pub 2015. PMID: 26327783.
195. Woodson AH, Profato JL, Rizvi SH, Elsayegh N, Rieber AG, Arun BK. Service delivery model and experiences in a cancer genetics clinic for an underserved population. J Health Care Poor Underserved 26(3):784-91, 2015. e-Pub 2015. PMID: 26320913.
196. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Intl J Oncol 47(1):262-8, 2015. e-Pub 2015. PMID: 25975349.
197. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. e-Pub 2015. PMID: 26092296.
198. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
199. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani MLO, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kuruan A, Laronga C, Layman RN, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw 13(7):880-915, 2015. e-Pub 2015. PMID: 26150582.
200. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet 28(3):272-82, 2015. e-Pub 2015. PMID: 24646362.
201. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobagyi GN, Singletary CN, Hasmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation in male patients presenting for BRCA testing. Oncologist 20(6):593-7, 2015. e-Pub 2015. PMID: 25948675.
202. Bayraktar S, Gutierrez Barrera AM, Arun B, Jackson MA. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
203. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. J Cancer 6(7):610-5, 2015. e-Pub 2015. PMID: 26078790.
204. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK, …. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10(4):e0120020. doi:10.1371, 2015. e-Pub 2015. PMID: 25830658.
205. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Consortium C, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347-61, 2015. e-Pub 2015. PMID: 25849179.
206. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z. Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years. Mol Carcinog 54(4):281-90, 2015. e-Pub 2015. PMID: 24166930.
207. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Cook J, Arun BK, ……. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 17:61, 2015. e-Pub 2015. PMID: 25925750.
208. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Arun B. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47(2):164-71, 2015. e-Pub 2015. PMID: 25581431.
209. Profato JL, Arun B. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol 27(1):1-5, 2015. e-Pub 2015. PMID: 25502427.
210. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269-75, 2015. e-Pub 2015. PMID: 25224030.
211. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB, Ol O, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 24(1):308-16, 2015. e-Pub 2015. PMID: 25336561.
212. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 111(1):66-80, 2015. e-Pub 2015. PMID: 25381882.
213. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770-4, 2014. e-Pub 2014. PMID: 25231195.
214. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology 23(11):1220-8, 2014. e-Pub 2014. PMID: 24706506.
215. Elsayegh N, Kuerer HM, Lin H, Gutierrez-Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol 21(11):3466-3472, 2014. e-Pub 2014. PMID: 24796968.
216. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobagyi GN, Arun B, Petersen SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. e-Pub 2014. PMID: 24951607.
217. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 2014. e-Pub 2014. PMID: 24072553.
218. Biswas S, Arun B, Parmigiani G. Reclassification of predictions for uncovering subgroup specific improvement. Stat Med 33(11):1914-27, 2014. e-Pub 2014. PMID: 24353130.
219. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 2014. e-Pub 2014. PMID: 24522996.
220. Chandwani K, Perkins G, Nagendra H, Raghurham NV, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Haddad R, Morris GS, Scheetz J, Chaoul A, Cohen L. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol 32(10):1058-65, 2014. e-Pub 2014. PMID: 24590636.
221. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon Y, Cajal T, Konstantopoulou I, Martinez-Bouzas C, Andres Conejero R, Soucy P, McGuffog L, Barrowdate D, Lee A, Swe-Brca Arver B, Rantala J, Loman N, Ehrencrona H, Ol O, Beauttie MS, Domcheck SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10(4):e1004256 doi: 10.137/journal.pgen.1004256, 2014. e-Pub 2014. PMID: 24698998.
222. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II study of gemcitabine and vinorelbine in heavily pretreated patients with metastatic breast cancer and review of the literature. J Cancer 5(5):351-9, 2014. e-Pub 2014. PMID: 24723978.
223. Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B, Palmer JL, Taylor J, Cohen L. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22(10):2354-63, 2013. e-Pub 2013. PMID: 23657969.
224. Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer 4(5):433-446, 2013. e-Pub 2013. PMID: 23833688.
225. Bayraktar S, Avery T, Altundag K, Broglio K, Arun BK. Association between tumor characteristics and bone mineral density in postmenopausal breast cancer patients. Breast J 19(4):431-434, 2013. e-Pub 2013. PMID: 23701522.
226. Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI, Arun B, Parmigiani G. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571-579, 2013. e-Pub 2013. PMID: 23690142.
227. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642, 2013. e-Pub 2013. PMID: 23370825.
228. Bojesen SE, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collee JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Breasac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45(4):371-84, 2013. e-Pub 2013. PMID: 23535731.
229. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267-74, 2013. e-Pub 2013. PMID: 23224828.
230. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. e-Pub 2013. PMID: 23231005.
231. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-17, 2013. e-Pub 2013. PMID: 23337751.
232. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist 18(5):493-500, 2013. e-Pub 2013. PMID: 23635555.
233. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericsen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Genetics Network OC, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Ol O, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmana J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, HEBON, EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ, Collaborators GS, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, CIMB. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PloS Genet 9(3):e1003212. doi: 10.1371, 2013. e-Pub 2013. PMID: 23544013.
234. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012. e-Pub 2012. PMID: 22622473.
235. de la Cruz J, Andre F, Harrell RK, Jr BR, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol 43(11):1932-1939, 2012. e-Pub 2012. PMID: 22591913.
236. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: Clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. e-Pub 2012. PMID: 22895267.
237. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5(9):1144-1154, 2012. e-Pub 2012. PMID: 22827973.
238. Kuerer HM, Lari SA, Arun B, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
239. Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet 1(2):pii: 104, 2012. e-Pub 2012. PMID: 26097796.
240. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J 18(3):261-6, 2012. e-Pub 2012. PMID: 22583196.
241. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. e-Pub 2012. PMID: 22590484.
242. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun B, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 132(3):1147-55, 2012. e-Pub 2012. PMID: 22218884.
243. Bayraktar S, Elsayegh N, Gutierrez-Barerra AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstram F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2012. PMID: 22009639.
244. Arun BK, Valero V, Liu D, Brewster AM, Green M, Gutierrez-Barerra A, Green M, Gutierrez-Barerra AM, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res 5(2):276-82, 2012. e-Pub 2012. PMID: 22102688.
245. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. e-Pub 2012. PMID: 21761402.
246. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. e-Pub 2012. PMID: 22242911.
247. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. e-Pub 2012. PMID: 21913181.
248. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347-55, 2012. e-Pub 2012. PMID: 22270937.
249. Ready K, Arun B, Schmeler KM, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. e-Pub 2011. PMID: 21681553.
250. Ready K, Arun B, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. e-Pub 2011. PMID: 21681553.
251. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. e-Pub 2011. PMID: 21830012.
252. Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila) 4(11):1852-62, 2011. e-Pub 2011. PMID: 21778330.
253. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 28(29):3739-3746, 2011. e-Pub 2011. PMID: 21900106.
254. Roses RE, Arun B, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 18(10):2873-8, 2011. e-Pub 2011. PMID: 21476105.
255. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-3907, 2011. e-Pub 2011. PMID: 21365619.
256. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun B, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-2667, 2011. e-Pub 2011. PMID: 21656744.
257. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496-503, 2011. e-Pub 2011. PMID: 21441069.
258. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun B, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089, 2011. e-Pub 2011. PMID: 21233401.
259. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun BK. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, 2011. e-Pub 2011. PMID: 21294809.
260. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
261. Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, LePetross C, Dogan B, McKenna BJ, Markman M, Babiera G. External qigong therapy for women with breast cancer prior to surgery. Integrative Cancer Therapies 9(4):348-353, 2010. e-Pub 2010. PMID: 21106615.
262. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Breast Cancer KCCFRIF, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat 124(2):441-51, 2010. e-Pub 2010. PMID: 20309627.
263. Zhang D, Tari AM, Akar U, Arun B, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther 9(11):3090-9, 2010. e-Pub 2010. PMID: 21045138.
264. Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw 8(10):1148-55, 2010. e-Pub 2010. PMID: 20971839.
265. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compr Cancer Netw 8(10):1112-46, 2010. e-Pub 2010. PMID: 20971838.
266. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28(25):3917-3921, 2010. e-Pub 2010. PMID: 20679610.
267. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-20, 2010. e-Pub 2010. PMID: 20733129.
268. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun B, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-487, 2010. e-Pub 2010. PMID: 20431955.
269. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: large and small trials. Semin Oncol 37(4):367-383, 2010. e-Pub 2010. PMID: 20816507.
270. Yi M, Hunt KK, Arun B, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-1034, 2010. e-Pub 2010. PMID: 20647335.
271. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244, 2010. e-Pub 2010. PMID: 20609467.
272. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun B, Wang LE. The funtional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-249, 2010. e-Pub 2010. PMID: 20033770.
273. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 28(5):554-559, 2010. e-Pub 2010. PMID: 20210524.
274. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub 2010. PMID: 20423989.
275. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 3(6):355-365, 2010. e-Pub 2010. PMID: 20222793.
276. Perez A, Arun B, Tripathy D, Tagliaferri M, Shaw H, Kimmick G, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Wittes J, Shapiro C. Phase 1B dose escalation trial of scutellaria barbata (BZL 101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-118, 2010. e-Pub 2010. PMID: 20054647.
277. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010. e-Pub 2010. PMID: 20054647.
278. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-314, 2010. e-Pub 2010. PMID: 19241157.
279. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR, Wei Q, Cohen L. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol 8(2):43-55, 2010. e-Pub 2010. PMID: 20388445.
280. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun B, Letrent S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64(6):1139-48, 2009. e-Pub 2009. PMID: 19294387.
281. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O, Arun B, Lu K, Bovin N. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 46(15):3037-49, 2009. e-Pub 2009. PMID: 19608278.
282. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258, 2009. e-Pub 2009. PMID: 19470930.
283. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, HortobagyiGN, Arun B. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
284. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-971, 2009. e-Pub 2009. PMID: 19172584.
285. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115(4):725-730, 2009. e-Pub 2009. PMID: 19127556.
286. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2(2):122-7, 2009. e-Pub 2009. PMID: 19174581.
287. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2009. e-Pub 2009. PMID: 18581139.
288. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ, Winchester DJ, Anderson BO, Arun B, Bartelink H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA, Heywang-Köbrunner SH, Howell A, Isaacs C, Kopans DB, Mansel RE, Masood S, Palazzo JP, Pressman PI, Solin LJ, Untch M. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J 15(1):4-16, 2009. e-Pub 2009. PMID: 19141130.
289. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. e-Pub 2008. PMID: 18776816.
290. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun B, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 2008. e-Pub 2008. PMID: 18515258.
291. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A, Hortobagyi G, Arun B. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-8, 2008. e-Pub 2008. PMID: 18779615.
292. Brewster A, Hortobagyi G, Broglio K, Kau S, Santa-Maria C, Arun B, Amad U, Buzdar A, Booser D, Valero V, Esteva F. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-83, 2008. e-Pub 2008. PMID: 18695137.
293. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 4(5):669-79, 2008. e-Pub 2008. PMID: 18424910.
294. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99(1):68-71, 2008. e-Pub 2008. PMID: 18560403.
295. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-7, 2008. e-Pub 2008. PMID: 18373644.
296. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Hortobagyi G, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. e-Pub 2008. PMID: 18300256.
297. Batista L, Lu KH, Beahm EK, Arun B, Bodukra D, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer 8:101, 2008. e-Pub 2008. PMID: 18410690.
298. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. e-Pub 2008. PMID: 18303485.
299. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007. e-Pub 2007. PMID: 17925560.
300. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. e-Pub 2007. PMID: 17676585.
301. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-48, 2007. e-Pub 2007. PMID: 17699874.
302. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745-51, 2006. e-Pub 2006. PMID: 17109443.
303. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440-7, 2006. e-Pub 2006. PMID: 16955504.
304. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107(6):1348-54, 2006. e-Pub 2006. PMID: 16909414.
305. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006. e-Pub 2006. PMID: 16874816.
306. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun B, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 2006. e-Pub 2006. PMID: 16946209.
307. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(14 Pt 1):4274-82, 2006. e-Pub 2006. PMID: 16857802.
308. Sneige N, Liu B, Yin G, Gong Y, Arun B. Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol 19(5):622-29, 2006. e-Pub 2006. PMID: 16528376.
309. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. e-Pub 2006. PMID: 16333852.
310. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354-60, 2006. e-Pub 2006. PMID: 16421416.
311. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 2005. e-Pub 2005. PMID: 16322343.
312. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:33, 2005. e-Pub 2005. PMID: 16153302.
313. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-93, 2005. e-Pub 2005.
314. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 11(15):5401-9, 2005. e-Pub 2005. PMID: 16061854.
315. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14(7):1681-5, 2005. e-Pub 2005. PMID: 16030101.
316. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466-72, 2005. e-Pub 2005. PMID: 15852360.
317. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102(23):8315-20, 2005. e-Pub 2005. PMID: 15914550.
318. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005. e-Pub 2005. PMID: 15738535.
319. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89(2):149-57, 2005. e-Pub 2005. PMID: 15692757.
320. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26(3):271-4, 2005. e-Pub 2005. PMID: 15991524.
321. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. e-Pub 2004. PMID: 15389473.
322. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. e-Pub 2004. PMID: 15136595.
323. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2004. e-Pub 2004. PMID: 14698135.
324. Ozguroglu M, Avci B, Turna H, Esen G, Arun B, Celik V, Serdengecti S. Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women. Med Oncol 21(2):139-43, 2004. e-Pub 2004. PMID: 15299186.
325. Altundag K, Altundag O, Gunduz M, Arun B. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen. Med Hypotheses 63(5):823-6, 2004. e-Pub 2004. PMID: 15488654.
326. Altundag K, Arun B. Amerikan Klinik Kanser Cemiyeti (ASCO) Toplantisindan Izlenimler: Meme Kanserinin Adjuvan Tedavisinde Bisfosfonatlarin Rolu. The Turkish Journal of Hematology and Oncology 14(3):179-181, 2004. e-Pub 2004.
327. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 98(12):2554-9, 2003. e-Pub 2003. PMID: 14669273.
328. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. e-Pub 2003. PMID: 12972520.
329. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249-54, 2003. e-Pub 2003. PMID: 12947059.
330. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9(7):2406-15, 2003. e-Pub 2003. PMID: 12855612.
331. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800-8, 2002. e-Pub 2002. PMID: 11919237.
332. Arun B, Kilic G, Ashfaq R, Saboorian HM, Gokaslan T. Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest 19(8):779-82, 2001. e-Pub 2001. PMID: 11768030.
333. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2000. e-Pub 2000. PMID: 18026834.
334. Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S, Berkarda B. Serum erythropoietin level in anemic cancer patients. Med Oncol 17(1):29-34, 2000. e-Pub 2000. PMID: 10713657.
335. Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 6(1):21-4, 2000. e-Pub 2000. PMID: 10696734.
336. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S, Berkarda B. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost 5(3):181-184, 1999. e-Pub 1999. PMID: 10726005.
337. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A, Lippman ME. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant 23(7):667-73, 1999. e-Pub 1999. PMID: 10218842.
338. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 85(1):93-9, 1999. e-Pub 1999. PMID: 9921979.
339. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma 31(5-6):613-5, 1998. e-Pub 1998. PMID: 9922053.

Invited Articles

1. Arun B, Couch FJ, Abraham J, Tung N, Fasching PA. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer 131(9):1400-14, 2024. e-Pub 2024. PMID: 39215191.
2. Yam C, Patel M, Hill HA, Sun R, Jr BR, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-34, 2024. e-Pub 2024. PMID: 39356138.
3. Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 130(19):3251-71, 2024. e-Pub 2024. PMID: 38985794.
4. Michel AM, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, Anderson G, Arnold K, Law C, Pruthi S, Sandoval-Leon A, Shirley R, Perdekamp MG, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino DA, Wisinski K, DeYoung CA, Ross M, Floyd J, Kaster A, VanderWalde L, Saphner TJ, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Crew KD, Kukafka R. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904). BMC Med Inform Decis Mak 24(1):272, 2024. e-Pub 2024. PMID: 39334347.
5. Navsaria LJ, Haas AM, Corredor JL, Arun BK, Giordano SH, Nead KT, Wehner MR. Skin cancer risk in patients with BRCA mutations. JAAD Int 27(17):175-7, 2024. e-Pub 2024. PMID: 39525845.
6. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH. Breast cancer risk reduction. J Natl Compr Cancer Netw 5(8):676-01, 2007. e-Pub 2007. PMID: 17927926.
7. Arun B, Brown PH, Garber JE. Risk assessment and efficacy of pharmacologic agents in breast cancer. Updates in Current Clinical Practices 1:5-8, 2006. e-Pub 2006.
8. Altundag K, Esteva FJ, Arun B. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anticancer Agents 5(2):99-106, 2005. e-Pub 2005. PMID: 15777217.
9. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31(2 Suppl 7):22-9, 2004. e-Pub 2004. PMID: 15179621.
10. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist 9(6):599-05, 2004. e-Pub 2004. PMID: 15561804.
11. Arun B. An overview of breast cancer prevention trials. The American Journal of Oncology Review:492-94, 2003. e-Pub 2003.
12. Arun B. Management of women at high risk for breast cancer. JNCCN 1(1):S71-77, 2003. e-Pub 2003.
13. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002. e-Pub 2002. PMID: 12382190.
14. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 3(6):681-91, 2002. e-Pub 2002. PMID: 12036407.
15. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer 9(1):15-32, 2002. e-Pub 2002. PMID: 11914180.
16. Arun B. Preventive strategies for breast cancer. Breast Cancer: Management and Treatment Updates 1:1-11, 2002. e-Pub 2002.
17. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opin Pharmacother 2(3):491-505, 2001. e-Pub 2001. PMID: 11336601.
18. Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines. Eur J Gynaecol Oncol 20(3):167-71, 1999. e-Pub 1999. PMID: 10410876.
19. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. clinical and pathophysiological mechanisms and manifestations. Haemostasis 29(2-3):111-34, 1999. e-Pub 1999. PMID: 10629392.
20. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis 29(2-3):100-10, 1999. e-Pub 1999. PMID: 10629391.
21. Longo DL, Arun B. Clinical approach to cervical lymphadenopathy. Consultant 36(11):2345-2352, 1996. e-Pub 1996.

Review Articles

1. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228-e232, 2017. e-Pub 2017. PMID: 28368261.
2. Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 31:224-232, 2017. e-Pub 2017. PMID: 27931006.
3. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun B, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 27(2):279-88, 2009. e-Pub 2009. PMID: 19064970.
4. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. e-Pub 2006. PMID: 16778094.
5. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 47(3):269-81, 1998. e-Pub 1998. PMID: 9516081.

Professional Educational Materials

1. Arun B. Genetic testing for hereditary breast cancer, 2015.
2. Arun B. Management of high-risk patients. Breast Cancer and Genetics Oncology, 2013.
3. Arun B. Risk assessment and genetic testing. Breast Cancer and Genetics Oncology, 2013.
4. Arun B. Possible link discovered in Hispanic women and breast cancer. CBS - KHOU TV, 2007.
5. Arun B. The role BRCA mutations play in breast cancer risk. Golf for Women Magazine, 2007.

Other Articles

1. León-Letelier RA, Sevillano-Mantas AM, Chen Y, Park S, Vykoukal J, Fahrmann JF, Ostrin EJ, Garrett C, Dou R, Cai Y, Hsiao FC, Dennison JB, Vilar E, Arun BK, Hanash S, Katayama H Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells. Vaccines (Basel) 13(6):629, 2025. PMID: 40573960.
2. Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones S, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, den Hollander P, Ravenberg EE, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans WF, Chang JT, Piwnica-Worms H An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapy. bioRxiv 28(2024):11.25.625287, 2024. PMID: 39651299.
3. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. PMID: 26787237.
4. Ready K, Litton JK, Arun B Clinical application of breast cancer risk assessment models. Future Oncology 6(3):355-365, 2010. PMID: 20222793.
5. Arun B Commentary on the article Fenretinide Breast Cancer Prevention Trial: Drug and retinol plasma levels in relation to age and disease outcome. Breast Disease: A Year Book Quarterly, 2003.

Abstracts

1. Lanier, A, Garber, H, Guitierrez, A, Arun, B. Characteristics and outcome of breast cancers diagnosed in patients with germline ATM mutations. 2025 ASCO Annual Meeting 43(16), 2025. e-Pub 2025.
2. Woodson A, Al-Awadhi A, Gutierrez A, Sui D, Jr RB, Corredor J, Lozano G, Dinardo C, Arun B. Clinical characteristics and cancer spectrum among breast cancer patients with TP53 germline mutation from a single institution. 2025 ASCO Annual Meeting 43(16), 2025. e-Pub 2025.
3. Kizub D, Meza K, Cuevas AR, Amaram C, Vara A, Shanker S, Lee K, Arun B. Results of a program addressing multi-level barriers to completion of hereditary cancer genetic testing (GT) among underserved and minority individuals in Texas. 2025 ASCO Annual Meeting 43(16), 2025. e-Pub 2025.
4. Abdel-Salam H, Shilbauer R, Moskowitz JB, LaRose M, Mansfield PF, Arun B. Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT. J Clin Oncol 42(16):Poster Board #145, 2024. e-Pub 2024.
5. Akkoc Mustafayev FN, Gutierrez AM, Munsell MF, Chen J, Schlacher K, Tainer JA, Albarracin CT, Arun B. Evaluation of biomarkers of response in patients with breast cancer with BRCA 1/2 pathogenic variants treated with PARP inhibitors. 2024 ASCO Annual Meeting 42(16):Abstract # e15188, 2024. e-Pub 2024.
6. Abdel-Salam H, Shilbauer R, Moskowitz JB, LaRose M, Mansfield PF, Arun B. Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT. 2024 ASCO Annual Meeting 42(16):Abstract #10618, 2024. e-Pub 2024.
7. Akula V, Corredor J, Ramirez DL, Arun B. Pathways for provider initiated genetic testing to bridge the gap in germline genetic testing for metastatic breast cancer. 2024 ASCO Annual Meting 42(16):Abstract: e23239, 2024. e-Pub 2024.
8. Letelier RL, Katayama H, Chen Y, Cai Y, Hsiao F, Arun B, Hanas S. A novel citrullinated-ENO1 peptide-based vaccine for triple-negative breast cancer prevention. 2023 Annual SABCS 84(9):Abstract #PS07-06, 2024. e-Pub 2024.
9. Mustafayev FNA, Munsell M, Gutierrez-Barrera AM, Yam C, Layman RM, Arun B. Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience. J Clin Oncol 41(16):Abstract # 10587, 2023. e-Pub 2023.
10. Kizub DA, Shanker S, Green SG, Vara A, Arun B. Connecting Black families in Houston, Texas, to hereditary cancer genetic counseling, genetic testing, and cascade testing by using a simple cancer genetic risk assessment and telegenetics. J Clin Oncol 41(16):Abstract #TPS10638, 2023. e-Pub 2023.
11. Abdel-Salam H, Mansfield PF, Moskowitz JB, Arun A. CDH1 incidental findings in patients with personal or family history of breast cancer. J Clin Oncol 41(16):Abstract #10524, 2023. e-Pub 2023.
12. Akkoc Mustafayev FN, Munsell M, Gutierrez-Barrera AM, Yam C, Layman RM, Arun B. Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience. 2023 ASCO Annual Meeting 41(16):Abstract #10587, 2023. e-Pub 2023.
13. Abdel-Salam H, Mansfield PF, Moskowitz JB, Arun B. CDH1 incidental findings in patients with personal or family history of breast cancer. 2023 ASCO Annual Meeting 41(16):Abstract 10524, 2023. e-Pub 2023.
14. Kizub DA, Shanker S, Green S, Vara A, Arun B. Connecting Black families in Houston, Texas, to hereditary cancer genetic counseling, genetic testing, and cascade testing by using a simple cancer genetic risk assessment and telegenetics 41(16):Abstract TPS10638, 2023. e-Pub 2023.
15. Dodd-Eaton EB, Nguyen HN, Corredor J, Woodman-Ross J, Peng G, Green S, Hernandez ND, Gutierrez Barrera A, Arun B, Wang W. Determining concordance of LFSPRO TP53 germline carrier risk predictions to standard genetic counseling practice. 2022 ASCO Annual Meeting. J Clin Oncol 40(Suppl 16), 2022. e-Pub 2022.
16. Kizub DA, Bluebond R, Green S, Duckworth J, Shanker S, Vara A, Joseph B, Arun B. Improving access to cancer genetic testing for underserved women in southeast Texas. 2022 ASCO Annual Meeting. Citation: J Clin Oncol 40(Suppl 16; abstr 6548), 2022. e-Pub 2022.
17. Recio CCV, Corredor J, Dodd-Eaton E, Gutierrez-Barrera AM, Daw NC, Arun B, Wang W. Identification and characterization of de novo TP53 mutation carriers in Li-Fraumeni syndrome families: a single institution experience. 2021 ASCO Annual Meting, 2021. e-Pub 2021.
18. Abuhadra N, Chang CC, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. Identification and characterization of de novo TP53 mutation carriers in Li-Fraumeni syndrome families: A single institution experience. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
19. Wildiers H, Ayoub JP, Friedlander M, Kaufman B, Arun BK, Han HS, Puhalla SL, Maag D, Feng D, Ratajczak CK, Bach BA, Diéras V. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial. 2020 Annual San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
20. Abuhadra N, Yam C, Sun R, Huo L, White J, Ravenberg E, Adrada B, Sahin A, Litton J, Lim B, Ueno NT, B|| A, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Lucci A, Mittendorf E, Moulder S, Chang J. Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT). 2020 Annual San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
21. Al-Awadhi A, Abuhadra N, Liu DD, Barrera AMG, Corredor J, Strong LC, Arun BK. Clinical and Pathological Characteristics and Screening Outcome For Secondary Cancers In Breast Cancer Patients With Li-Fraumeni Syndrome Attending The MD Anderson Li-Fraumeni Education And Early Detection Program Clinic. 2020 Annual San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
22. Alameddine HF, Singareeka A, Andersen C, Selber J, Brewster A, Barcenas CH, Caudle A, Arun B, Ibrahim N. Decision making process and contralateral prophylactic mastectomy. 2020 Annual San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
23. Shukla MA, Barrera AG, Gruschkus SK, Layman RM, Murthy RK, BK <. Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCAmutations. 2020 Annual San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
24. Abuhadra N, Hess K, Litton J, Rauch G, Thompson A, Lim B, Adrada B, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang W, Ueno N, Santiago L, Murthy R, Ibrahim N, Aysegul S, Symmans W, Huo L, Moulder S. Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
25. Militello L, Gutierrez Barrera AM, Albarracin C, Bedrosian I, Arun BK. Clinical characteristics of breast cancer patients with ATM mutations. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
26. Makhnoon S, Arun B, Volk RJ, Peterson SK. Disclosure of familial implications of pathogenic BRCA1/2 to probands: Opportunity for prompting family communication. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
27. Militello L, Gutierrez Barrera AM, Kuerer H, Albarracin C, Arun BK. Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
28. Arun BK, Gierach G, Scoggins ME, Khan S, Rao SS, Garber J, Raza S, Kumar NB, Han HH, Heine J, Niell B, Chalasani P, Fitzpatrick K, Wilke LG, Fowler A, Beckwith HC, Mays C, Abutaseh S, Vornik L, Lee O, Dimond E, Perloff M, Liu D, Lee J, Brown P, Heckman-Stoddard B. A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
29. Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, J-P A, Puhalla SL, Bach BA, Dudley M, Ratajczak CK, Maag D, Diéras V. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
30. Garber H, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Tripathy D, Piwnica-Worms H, Symmans F, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
31. Carraro DM, Palmero EI, Berra CM, Torrezan GT, Brianese RC, Fernandes GC, Gutierrez Barrera AM, Galvo HC, Formiga MNC, Arun BK. Reclassification of variant of unknown significance in BRCA1 and BRCA2 genes based on loss of Heterozigosity assay. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
32. Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, J-P A, Puhalla SL, Bach BA, Dudley M, Ratajczak CK, Maag D, Diéras V. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial. 2019 Annual SABCS Meeting, 2019. e-Pub 2019.
33. Chapman BSV, Liu DD, Stecklein SR, Barrera AG, Woodward WA, Arun B, Shaitelman SF, Sawakuchi GO. Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
34. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
35. Garber H, Raghavendra AS, Hess KR, Arun B, Ibrahim NK. Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
36. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
37. Montiel MF, Quesada PR, Dunseith M, Cazacu I, Luzuriaga A, Dong W, Bannon SA, Mork ME, Feng L, You YN, Sanchez EV, Arun B, Brown P, Kim MP, Katz MHG, Maitra A, Bhutani MS, McAllister F. New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
38. Ross J, Bell D, Yarbrough AR, Peterson SK, Makhnoon S, Arun B, Livingston JA, Roth M. Improving access to genetic counseling services in an adolescent and young adult (AYA) clinic. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
39. Pande M, Okon C, You YN, Peterson SK, Arun B, Lynch PM. Adequacy of self-reported family history in electronic health record for genetic risk assessment for Lynch syndrome. 2019 ASCO Annual ASCO Meeting, 2019. e-Pub 2019.
40. Hobbs E, Yang F, Kumar T, Contreras A, Cuentas ERP, Garber H, Scoggins M, Adrada BE, Whitman GJ, Arun B, Mittendorf EA, Litton JK. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. 2019 Annual ASCO Meeting, 2019. e-Pub 2019.
41. Al-Awadhi A, Liu DD, Gutierrez-Barrera AM, Strong LC, Arun BK. Clinical and pathological characteristics and screening outcome for secondary cancers of women with breast cancer and Li-Fraumeni syndrome. 2018 SABCS Annual SABCS Meeting Program number P5-09-02(Poster Sessiion 5), 2018. e-Pub 2018.
42. Brouwer WS, Woodson AH, Tran G, Arun B. Compliance with high-risk screening of unaffected BRCA1 and BRCA2 pathogenic variant carriers. J Clin Oncol 36, 2018. e-Pub 2018.
43. Litton JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). J Clin Oncol 36, 2018. e-Pub 2018.
44. SLr M, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 36, 2018. e-Pub 2018.
45. Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford LG, Arun B, Neuhouser M, Brown P. Randomized double-blind placebo-controlled biomarker modulation study of vitamin d in premenopausal women at high risk for breast cancer (SWOG S0812). J Clin Oncol 36, 2018. e-Pub 2018.
46. Daniels MS, Lu KH, Arun B, Routbort M, Broaddus R. Disclosure of secondary germline findings from clinical tumor-normal paired somatic mutation profiling. J Clin Oncol 36, 2018. e-Pub 2018.
47. Arun B, Schnabel FR, Chun J, Heeke AL, Smith JA, Roses DF, Kurz E, Landry K, Gutierrez Barrera A, Wood M, Isaacs C. Non-BRCA hereditary gene mutations and breast cancer phenotype: An ISC-RAM Consortia study. J Clin Oncol 36, 2018. e-Pub 2018.
48. Montiel MF, Quesada PR, Dunseith M, Sanchez EV, Bhutani MS, Kim MP, Katz MHG, Maitra A, Mork ME, Arun B, Bannon SA, McAllister F. Early outcomes of a high-risk cohort in pancreatic cancer surveillance. J Clin Oncol 36. e-Pub 2018.
49. Yam C, Gutierrez Barrera A, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing. 2017 Annual SABCS Meeting, 2017. e-Pub 2017.
50. Nielsen TO, Leung SCY, Zabaglo LA, Arun B, Badve SS, Bane AL, Bartlet JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, A-V L, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM. Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration. 2017 Annual SABCS Meeting, 2017. e-Pub 2017.
51. Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK, Arun B. Multi-gene panel testing results in patients with multiple breast cancer primaries. 2017 Annual SABCS Meeting, 2017. e-Pub 2017.
52. Litton JK, Scoggins M, Whitman GJ, Barcenas CH, Moulder SL, Murthy RK, Abouharb S, Adrada B, Helgason T, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Arun B. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. J Clin Oncol 35, 2017. e-Pub 2017.
53. Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah VS, Hong DS, Woodman SE, Mendelsohn J, Yap TA, Mills GB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. J Clin Oncol 35, 2017. e-Pub 2017.
54. Dumbrava EAI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Routbort M, Piha-Paul SA, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. J Clin Oncol 35, 2017. e-Pub 2017.
55. Gutierrez-Barrera AM, Schvartsman G, Song J, Ueno NT, Peterson SK, Arun B. Association between weight gain during adjuvant chemotherapy (CTx) for early-stage breast cancer (BC) and survival outcomes. J Clin Oncol 35, 2017. e-Pub 2017.
56. Arun B, Elsayegh N, Lin HY, Clifton K, Gutierrez-Barrera AM, Litton JK, Albarracin CT. Breast cancer phenotype in patients with hereditary gene mutations other than BRCA1 and BRCA2. J Clin Oncol 35, 2017. e-Pub 2017.
57. Scoggins M, Dogan B, Ma J, Wei W, Song JB, Candelaria RP, Litton JK, Arun B. Short breast MRI screening trial in women at high-risk for breast cancer. J Clin Oncol 35, 2017. e-Pub 2017.
58. Kushwaha AC, Sweeney LE, Ghosh N, Arun B. High Risk Genetic Screening Program in a Community Hospital Breast Imaging Center. J Clin Oncol 35, 2017. e-Pub 2017.
59. Clifton K, Gutierrez Barrera A, Ma J, Bassett RL, Litton JK, Arun B. Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients. J Clin Oncol 35, 2017. e-Pub 2017.
60. Peterson SK, Strong L, Schembre S, Cox M, Li L, Karam C, Song J, Arun B, Pande M, You YN, Rodriguez-Bigas MA, Lu KH, Lynch PM, Basen-Engquist K. Health4Families: An intervention to improve weight and health behaviors in families with hereditary breast/ovarian cancer or Lynch syndrome. J Clin Oncol 35, 2017. e-Pub 2017.
61. Gelpi JB, Lubinski JA, Arun B, Byrski T, Telli ML, Isakoff SJ, Fernandez C, Lardelli P, Kahatt CM, Soto-Matos A, Delaloge S. Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials. J Clin Oncol 35, 2017. e-Pub 2017.
62. Shafaee MN, Sinha AK, Saigal B, Murthy RK, Syed MP, Woodson AH, Arun B, Barcenas CH. Referral for genetic counseling in survivors of triple negative breast cancer (TNBC): An ongoing objective. J Clin Oncol 34, 2016. e-Pub 2016.
63. Shafaee MN, Lin HY, Gutierrez Barrera A, Arun B. Oncotype Dx analysis in early stage breast cancer (BC) in BRCA mutation carriers versus non-carriers. J Clin Oncol 34, 2016. e-Pub 2016.
64. Muse KI, Bednar E, Emborgo TS, Oakley HD, Litton JK, Peterson SK, Lu KH, Arun B. Universal BRCA testing of TNBC and HGSOC and active family outreach to increase identification of at-risk relatives for cascade testing. J Clin Oncol 34, 2016. e-Pub 2016.
65. Matsuda N, Wang X, Krishnamurthy S, Alvarez RH, Willey JS, Lim B, Parker CA, Babiera G, Booser DJ, Murray JL, Arun B, Brewster AM, Reuben JM, Stauder MC, Woodward WA, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. J Clin Oncol 34, 2016. e-Pub 2016.
66. Weitzel JN, Frankel PH, Herzog J, Arun B, Beumer JH, Ma CX, Cigler T, Cream L, Harvey HA, Sparano JA, Nanda R, Chew HK, Vahdat LT, Goetz MP, Gandara DR, Piekarz R, Tongeren LRV, Ferry-Galow KV, Synold TW, Somlo G. Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC). J Clin Oncol 34, 2016. e-Pub 2016.
67. French JT, Hess KR, Liu DD, Singh Raghav KP, Hortobagyi GN, Arun B, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. J Clin Oncol 33:Suppl; abstr 1586, 2015. e-Pub 2015.
68. Diniz Gomes DB, Deeba RE, Suki D, Valero V, Moulder SL, Arun B, Higginbotham Koenig K, Strom EA, Hsu L, Sawaya R, Tripathy D, Ibrahim NK. Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999-2012. J Clin Oncol 33:Suppl; abstr 1046, 2015. e-Pub 2015.
69. Somlo G, Frankel PH, Luu TH, Ma CX, Arun B, Garcia AA, Cigler T, Cream L, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan J, Vahdat LT, Goetz MP, Hurria A, Mortimer JE, Gandara DR, Chen AP, Weitzel JN. Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC). J Clin Oncol 33:Suppl; abstr 520, 2015. e-Pub 2015.
70. Ardic C, Gutierrez-Barrera AM, Elsayegh N, Song J, Profato J, Litton JK, Giordano SH, Tripathy D, Arun B. Predictors of BRCA mutation in male breast cancer. J Clin Oncol 33:Suppl; abstr 15383 (selected for poster presentation), 2015. e-Pub 2015.
71. Moulder SL, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women's triple-negative first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). J Clin Oncol 33:Suppl; abstr TPS1113, 2015. e-Pub 2015.
72. Matsuda N, Alvarez RH, Krishnamurthy S, Willey JS, Wang X, Lim B, Parker CA, Marx A, Babiera G, Booser DJ, Murray JL, Arun B, Brewster AM, Reuben JM, Woodward WA, Lucci A, Gainer SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. J Clin Oncol 33:Suppl; abstr 1065, 2015. e-Pub 2015.
73. Puhalla S, Han HS, Dieras V, Friedlander M, Somlo G, Arun B, Widiers H, Kaufman B, Ayoub JPM, Shan M, Burmedi D, Qin Q, Quian J, Giranda VL, Peacock Shepherd S. Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC). J Clin Oncol(33):Suppl; abstr TPS1102, 2015. e-Pub 2015.
74. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol 33:Suppl; abstr 1510 (Oral presentation), 2015. e-Pub 2015.
75. Murthy RK, Ueno NT, Symmans WF, Litton JK, Arun BK, Ibrahim NK, Alvarez RH, Gilcrease MZ, Valero V, Tripathy D, Moulder SL. Phase II single arm study of liposomal doxorubicin (D), evacizumab (A), and temisirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy. 2014 Annual SABCS Meeting, 2014. e-Pub 2014.
76. Stauder MC, Shaitelman SF, Allen PK, Brewster AM, Arun BK, Woodward WA, Buchholz TA, Wang LE. Gamma-ray induced mutagen sensitivity and overall survival in young women with breast cancer. 2014 Annual SABCS Meeting:abstr P3-08-01 (selected for poster presentation), 2014. e-Pub 2014.
77. Elsayegh N, Lin HY, Gutierrez-Barrera AM, Profato J, Litton JK, Kuerer HM, Hortobagyi GN, Arun B. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who tested negative for a BRCA mutation. ASCO Breast Cancer Symposium:abstr 42 (selected for poster presentation), 2014. e-Pub 2014.
78. Gomes DBD, Deeba RE, Valero V, Moulder SL, Arun B, Alvarez RH, Hsu L, Ibrahim NK. Impact of chemotherapy and radiation therapy on local control and survival of metastatic breast cancer to the brain: Single-institution review of 792 cases. ASCO:abstr 146 (selected for poster presentation), 2014. e-Pub 2014.
79. Mitri ZI, Jackson M, Garby C, Giordano SH, Hortobagyi GN, Singletary C, Hashmi SS, Arun B, Litton JK. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing. J Clin Oncol 32(5s):Suppl; abstr 1559 (selected for poster presentation), 2014. e-Pub 2014.
80. Murthy RK, Chen H, Wei C, Jackson MA, Woodson AH, Litton J, Arun BA, Valero V, Barcenas CH. Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. J Clin Oncol 32(5s):Suppl; abstr 9589 (selected for poster presentation), 2014. e-Pub 2014.
81. Gutierrez-Barrera AM, Arun BK, yang P, Cartwright C. Zyflamend, a multi-herbal product, selectively inhibits the growth of triple negative breast cancer cells in vitro. Proc Am Ass Cancer Res:abstr 3218 (selected for poster presentation), 2014. e-Pub 2014.
82. Cohen L, Spelman A, Engle R, Arun B, Wei Q, Harrison C, Perkins GH, Valero V, Babiera G, Wangyal T, Chaoul A. Randomized trial of Tibetan yoga in breast cancer patients undergoing chemotherapy. J Clin Oncol 32(5s):Suppl; abstr 9539 (selected for poster presentation), 2014. e-Pub 2014.
83. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Arun B, Chavez-Macgregor M, Alvarez RH, Lucci A, Krishnamurthy S, Hortobagyi GN, Valero V, Ueno NT. Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer. 2013 Annual SABCS Meeting:abstr P6-12-02 (selected for poster presentation), 2013. e-Pub 2013.
84. Somlo G, Frankel P, Luu T, Ma C, Arun B, Garcia A, Cigler T, Fleming G, Harvey H, Sparano J, Nanda R, Chew H, Moynihan T, Vahdat L, Goetz M, Hurria A, Mortimer J, Gandara D, Chen A, Weizel J. Efficacy of ABT-88 (veliparib) in patients with BRCA-associated breast cancer. 2013 Annual SABCS Meeting:abstr PS-16-05 (selected for poster discussion), 2013. e-Pub 2013.
85. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woddson A, Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer. 2013 Annual SABCS Meeting:abstr 977 (selected for poster presentation), 2013. e-Pub 2013.
86. Afrough A, Lin H, Gutierrez-Barrera AM, Litton JK, Valero V, Arun B. Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment. J Clin Oncol 31:Suppl; abstr e12550, 2013. e-Pub 2013.
87. Arun BK. Assessing the added value of breast tumor markers in breast cancer genetic risk prediction model BRCAPRO. ASCO Breast Cancer Symposium:abstr 164 (selected for poster presentation), 2012. e-Pub 2012.
88. Woodson AH, Muse KI, Jackson M, Arun B, Litton JK. Impact of breast cancer and BRCA mutations on thoughts and feelings of future pregnancies. ASCO:abstr 38 (selected for poster presentation), 2012. e-Pub 2012.
89. Lee BN, Arun BK, Cohen EN, Tin S, Gutierrez-Barrera AM, Miura T, Kiyokawa I, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM. Sialyl Lewis and inflammatory mediators in breast cancer patients: Biological correlations and prognostic value. Cancer Res 72(24 Suppl):255s; abst PS-10-32 (selected for poster presentation), 2012. e-Pub 2012.
90. Elsayegh N, Gutierrez-Barrera AM, Muse KI, Lin H, Turco DL, Litton JK, Kuerer HM, Arun B. Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. J Clin Oncol 30(suppl):abstr 1549 (selected for poster presentation), 2012. e-Pub 2012.
91. Holman LL, Daniels MS, Brandt AC, Arun B, Keeler E, Gershenson DM, Sun CC, Lu KH. Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation previvors. J Clin Oncol 30:Suppl; abstr 1518, 2012. e-Pub 2012.
92. Brandt AC, Elsayegh N, Lin H, Gutierrez-Barrera AM, Lu KH, Arun B. Comparison of BRCA1/2-positive and negative women diagnosed with metachronous breast and ovarian cancers. J Clin Oncol 30:Suppl; abstr 1546 (selected for poster presentation), 2012. e-Pub 2012.
93. Basen-Engquist K, Murray JL, Baum G, Gutierrez-Barrera AM, Arun B. Randomized pilot study of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy. J Clin Oncol 30(Suppl; abstr e11090), 2012. e-Pub 2012.
94. Akar U, Gutierrez-Barrera A, Hortobagyi GN, Arun B. The PARP inhibitor AZD2281 induces autophagy and complete cell death in BRCA mutant breast cancer cell lines. Proc Am Ass Cancer Res 53:615; abst 2539 (selected for poster presentation), 2012. e-Pub 2012.
95. Zhang D, Akar U, Arun BK, Hortobagyi GN, Ueno NT. Acquired erlotinib resistance is associated with epithelial-mesenchymal transition and promotes metastasis in inflammatory breast cancer. Proc Am Ass Cancer Res:abstr 3583 (selected for poster presentation), 2011. e-Pub 2011.
96. Reuben JM, Arun B, Lee B, Galland M, Cohen EN, Tin S, Tang NK, Yang TM, Gutierrez-Barrera AM, Kiyokawa I, Miura T, Valero V, Ueno NT, Cristofanilli M. Elevated serum levels of Sialyl Lewis X (sLeX) and inflammatory cytokines in patients with nonmetastatic breast cancer. J Clin Oncol 29:Suppl; abstr e11061, 2011. e-Pub 2011.
97. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with history of hormone receptor-negative breast cancer. J Clin Oncol 28(15s):Suppl; abstr TPS142, 2010. e-Pub 2010.
98. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase interacting strathmin gene enhances erlotinib sensitivity by inhibiting serine 10 p27 phosphorylation in EGFR-expressing breast cancer. Proc Am Ass Cancer Res:abstr 1972 (selected for poster presentation), 2010. e-Pub 2010.
99. Jackson M, Brandt A, Gutierrez-Barrera A, Meric-Bernstam F, Litton JK, Lu HK, Hortobagyi GN, Arun B. Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. J Clin Oncol 28(15s):Suppl; abstr 6060, 2010. e-Pub 2010.
100. Meric-Bernstam F, Gutierrez-Barrera A, Litton JK, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun B. Mutation position in BRCA-associated breast cancers. J Clin Oncol 28(15s):Suppl; abstr 1542, 2010. e-Pub 2010.
101. Yang W, Sahin A, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B, Chang J. Molecular portraits of mammorgraphic breast density in normal breast tissue. JCO 26(15s):767s, 2008. e-Pub 2008.
102. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA variants of uncertain significance. JCO 26(15s):750s, 2008. e-Pub 2008.
103. Arun B, Atchley D, Litton J, Pusztai L, Valero V, Hortobagyi G, Albarracin C. Response to neoadjuvant chemotherapy in BRCA1 and BRCA2 related breast cancers. JCO 26(15s):35s, 2008. e-Pub 2008.
104. Cohen L, Chandwani K, Perkins G, Thornton B, Arun B, Raghuram N, Nagendra H. Randomized trail of yoga in women with breast cancer undergoing radiation treatment: Long-term effects. JCO 26(15s):536s, 2008. e-Pub 2008.
105. Ready K, Voguel K, Atchley D, Amos C, Solomon K, Lu K, Arun B. BRCA mutations among women with bilateral breast cancer: mutation carrier rate and sensitivity of the BRCAPRO model based on age at first diagnosis. 2007 Annual SABCS Meeting, 2007. e-Pub 2007.
106. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of Triple-negative versus HER2+ AND ER+ breast cancers. 2007 Annual SABCS Meeting, 2007. e-Pub 2007.
107. Arun B, Vuskovic M, Vasiliu D, Xu HY, Atchley D, Chambers J, Bovin N, Sneige N, Hortobagyi GN, Hufleit M. Immunomodulatory effects of celecoxib in patients at increased risk for breast cancer. 2007 Annual SABCS Meeting, 2007. e-Pub 2007.
108. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc:995, 2007. e-Pub 2007. PMID: 18694095.
109. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, White KG, Daniels MS, Arun B, Peterson SK, Bodurka DC. Management strategies for women at high risk for breast and ovarian cancer: Are women satisfied?. ASCO, 2007. e-Pub 2007.
110. Sun CC, Westin SN, Lu KH, Schmeler KM, White KG, Daniels MS, Arun B, Peterson SK, Bodurka DC. Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life (QOL). ASCO, 2007. e-Pub 2007.
111. Arun B, Logan C, Yin G, Yun G, Hortobagyi G, Browne, G, Sneige, N. Phase II prevention trial of celecoxib in women at increased risk for breast cancer. ASCO, 2007. e-Pub 2007.
112. Mazouni C, Hall A, Anderson K, Peintinger F, Fritsche H, Andre F, Yekell S, Arun B, Buzdar AU, Esteva F, Pusztai L, Cristofanilli M. An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment. 2006 Annual SABCS Meeting, 2006. e-Pub 2006.
113. Yang WT, Dryden M, Broglio K, Meric-Bernstam F, Valero V, Arun B. Mammographic and sonographic features of breast cancer in young women at high genetic risk. 2006 Annual SABCS Meeting, 2006. e-Pub 2006.
114. Arun B, Valero V, Logan C, Rivera E, Brewster A, Green M, Buzdar A, Browne D, Hortobagyi GN, Sneige N. Random periareolar fine needle aspiration compared to ductal lavage for tissue acquisition in short-term breast cancer chemoprevention studies. 2006 Annual SABCS Meeting, 2006. e-Pub 2006.
115. Solomon TL, Vogel KJ, Atchley DP, Amos C, Valero V, Meric F, Hortobagyi G, Arun B. High-risk precursor lesions observed in breast cancer patients who are positive for BRCA1 or BRCA2 mutations. 2006 Annual SABCS Meeting, 2006. e-Pub 2006.
116. k V, Atchley D, Erlichman J, Broglio K, Ready K, Amos C, Lu K, Valero V, Strong L, Hortobagyi G, Arun B. Evaluation of the BRCAPRO model in a cohort of Hispanic families. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research;, 2006. e-Pub 2006.
117. Huflejt M, Vuskovic M, Mazouni C, Vasiliu D, Xu H, Chambers J, Buzdar A, Arun B, Bovin N, Cristofanilli M, Pusztai L. Detection of anti-glycan autoantibodies with printed glycan arrays in primary breast cancer: diagnostic and predictive antibody signatures. 2006 Annual SABCS Meeting, 2006. e-Pub 2006.
118. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment. American Psychosomatic Society Conference, Denver, 2006. e-Pub 2006.
119. Cohen L, Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H. Randomized trail of yoga in women with breast cancer undergoing radiation treatment. J Clin Oncol 24:469s, 2006. e-Pub 2006.
120. Arun B, Valero V, Yin G, Babiera G, Murray J, Browne D, Gong Y, Cook E, Hortobagyi G, Sneige N. Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer. J Clin Oncol 24:18s, 2006. e-Pub 2006.
121. Rivera E, Meija J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Esteva F, Hortobagyi G, Valero V. Phase II study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results. J Clin Oncol 24:18s, 2006. e-Pub 2006.
122. Uyei A, Broglio K, Solomon T, Vogel K, Amos C, Lu K, Meric-Bernstam F, Strong L, Arun B. Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA 1/2 genetic mutation. J Clin Oncol 24:18s, 2006. e-Pub 2006.
123. Sneige N, Gong Y, Lammey J, Valero V, Babiera G, Kuerer H, Hortobagyi G, Arun B. Baseline proliferation markers and cytophatholic finds in breast epithelium of women at increased risk for breast cancer. JCO 23:884s, 2005. e-Pub 2005.
124. Arun B, Mohsin A, Miller A, Isaacs C, Saxton K, Hilsenbeck S, Lamph W, Johnson K, Brown P, Elledge R. Acquisition of breast tissue in a biomarker modulation study using bexarotene in women at high risk of breast cancer. JCO 23(16S):106s, 2005. e-Pub 2005.
125. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Sneige N, Buchholz TA, Hunt KK, Meric-Bernstam F, Arun B, Kuerer HM. The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT). J Clin Oncol 23(16S):36s, 2005. e-Pub 2005.
126. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Vaero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age 35 or younger with Primary Breast Carcinoma. Cancer, 2005. e-Pub 2005.
127. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment. International Yoga Conference, Bangalore, India, 2005. e-Pub 2005.
128. Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H, Cohen L. Randomized trial of yoga in women with breast cancer undergoing radiation treatment. The 2nd International Conference of the Society of Integrative Oncology, 2005. e-Pub 2005.
129. Altundag K, Kim E, Broglio K, Buzdar AU, Hortobagyi GN, Arun B. Characterization of bone mineral density (BMD) at the time of diagnosis in postmenopausal patients with operable breast cancer; Association with clinical-pathological findings. JCO 23(16S):864s, 2005. e-Pub 2005.
130. Deepali G, Sneige N, Katz R, Tarco E, Valero V, Babiera G, Green M, Hortobagyi GN, Arun B. Telomere length assessment in fine needle aspiration specimens of breast in women at high risk of breast cancer. Proc Amer Assoc Cancer Res 46:5727, 2005. e-Pub 2005.
131. Eder JP, Hidalgo M, Mendelson D, Ryan PD, Arun B, Lovalvo J, Eiseman I, Olson S, Lenehan P. A phase I clinic and pharmacokinetic (PK) study of oral CI-1033 + Docetaxel (DOC) in the treatment of patients with advanced solid tumors. JCO 23(16S):219s, 2005. e-Pub 2005.
132. Garcia MKP, Arun B, Albarracin C, Sneige N. Estrogen receptor (ER) expression in breast fine needle aspirates (FNA) of women at increased risk for breast carcinoma. Proc Amer Assoc Cancer Res 46:2106, 2005. e-Pub 2005.
133. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess K, Zhang W, Hortobagyi GN, Pusztai L. A single gene biomarker identifies undifferentiated breast cancers associated with short duration of breastfeeding. Breast Cancer Research and Treatment 94:s248, 2005. e-Pub 2005.
134. Arun B, Valero V, Hornbeak J, Gong Y, Broglio K, Logan C, Browne D, Hortobagyi G, Sneige N. Celecoxib downregulates estrogen receptor expression in breast tissue of women at increased risk for developing breast cancer. Breast Cancer Research and Treatment 94:s169, 2005. e-Pub 2005.
135. Erlichman J, Valero V, Lu K, Rivera E, Strong L, Arun B. Genetic testing for BRCA1 and BRCA2 mutations in the Hispanic population. Breast Cancer Research and Treatment 94:s166, 2005. e-Pub 2005.
136. Symmans WF, Sotiriou C, Anderson SK, Hatzis C, Valero V, Booser DJ, Larsimont D, Desmedt C, Gold DL, Sneige N, Cristofanilli M, Arun B, Gong Y, Ross JS, Hess K, Piccart MJ, Harris AL, Hortobagyi GN, Pusztai L. Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. Breast Cancer Research and Treatment 94:s32, 2005. e-Pub 2005.
137. Uyei A, Erlichman J, Lu K, Meric-Bernstam F, Strong L, Arun B. Risk reduction choices of women with deleterious BRCA1 and BRCA2 mutations at a single institution. Breast Cancer Research and Treatment 94:S25, 2005. e-Pub 2005.
138. Arun B, Lammey J, Broglio K, Valero V, Babiera G, Browne D, Hortobagyi GN, Sneige N. Downregulation of Estrogen receptor expression with Celecoxib in breast tissue of women at increased risk for developing breast cancer. 2004 Annual SABCS Meeting 88(1):S157, 2004. e-Pub 2004.
139. Carlson RW, Schurman CM, Rivera E, Chung CT, S-C P, Dice EK, Arun B, Thomas E, Valero V. Goserelin plus Anastrozole for the treatment of pre-menopausal women with hormone receptor positive, recurrent/metastatic breast cancer. 2004 Annual SABCS Meeting 88(1):S237, 2004. e-Pub 2004.
140. Cabioglu N, Yazici MS, Arun, B, Smith T, Hortobagyi GN, Price JE, Sahin AA. Novel biomarkers predicting axillary lymph node metastasis in small size breast cancer. 2004 Annual SABCS Meeting 88(1):S69, 2004. e-Pub 2004.
141. Arun B, Dice K, Albarracin C, Rivera E, Walters R, Theriault R, Booser D, Bast R, Cristofanili M, Sahin A, Smith TL, Hortobagyi GN. The combination of Letrozole and Imatinib Mesylate for metastatic breast cancer. 2004 Annual SABCS Meeting 88(1):S235, 2004. e-Pub 2004.
142. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, J-N C, Clarke CH, Arun B, M-C H, Kuerer HM. Significant differences in ductal fluid protein expression in healthy women versus those with breast cancer identified by time-of-flight mass spectrometry. 2004 Annual SABCS Meeting 88(1):S189, 2004. e-Pub 2004.
143. Cristofanilli M, Krishnaumurthy S, Guerra L, Arun B, Walters R, Booser DJ, Green MC, S-W K, Menander K, Van Wart HJ, Valero V, Hortobagyi, GN. Advexin (Ad5CMV-p53) combined with Docetaxel (T) and Doxorubicin (D) as induction chemotherapy (IC): significant efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer (LABC). 2004 Annual SABCS Meeting 88(1):S61, 2004. e-Pub 2004.
144. Cabioglu N, Yazici MS, Arun B, Smith TL, Hortobagyi GN, Price JE, Sahin A. Expression of CCR4 predicts lymph node ;metastasis in early breast cancer. Proc Am Soc Oncol 23:837, 2004. e-Pub 2004.
145. Ozlem E, Frye D, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with liver metastases only treated with chemotherapy. 29th ESMO Congress 15(3):iii46, 2004. e-Pub 2004.
146. Gonzalez-Angulo AM, Broglio K, S-W K, Erlap Y, Erlichman J, Valero V, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women Age 35 years or younger with primary breast carcinoma: disease features at presentation. 29th ESMO Congress 15:iii58, 2004. e-Pub 2004.
147. Esteva FJ, Madden TL, Lammey J, Symmans WF, Booser DJ, Arun B, Rivera E, Brewster AM, Valero V, Hortobagyi GN. Phase I and pharmacokinetic (PK) study of oblimersen, a proapoptotic Bcl-2 targeting oligonucleotide, in a combination with Doxorubicin and Docetaxel in metastatic and locally advanced breast cancer (BC). Proc Am Soc Oncol 23:224, 2004. e-Pub 2004.
148. Eralp Y, Smith TL, Kau SW, Valero V, Buzdar A, Hortobagyi GN, Arun B. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. Proc Am Soc Oncol 23:27, 2004. e-Pub 2004.
149. Arun B, Bariera G, Lammey J, Hortobagyi G, Sneige N. Phase II chemoprevention trial of Celecoxib using ductal lavage. 2003 Annual SABCS Meeting 82(1):S26, 2003. e-Pub 2003.
150. Moshin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW, Browh PH. Breast cancer prevention using RXR-selective retinoid (Targretin) in high risk women initial report of a phase II randomized clinical trial. 2003 Annual SABCS Meeting 82(1):S176, 2003. e-Pub 2003.
151. Lu K, Beahm E, Arun B, Boudurka-Bevers D, Sun C, Miller M, Hunt K, Ames F, Strong L, Meric-Bernstam F. Coordinated prophylactic surgical management for women with breast-ovarian cancer syndrome. Proc AACR Frontiers in Cancer Prevention Research 2nd Annual International Conference, Phoenix, AZ, 2003. e-Pub 2003.
152. Arun B, Kamal A, Middleton L, Wang X, Smith TL, Esteva F, Hortobagyi G, Sahin A. Evaluation of biomarkers to predict regional lymph node metastasis in early breast cancer; a significant correlation with BCL-2 expression. Proc Am Ass Can Res 44:545, 2003. e-Pub 2003.
153. Goncharuk V, Arun B, Middleton L, Sahin, A. Assessment of actin-binding fascin expression in stage I and II invasive breast cancer. A significant correlation with aggressive clinical behavior. Modern Pathology 16(1):39A, 2003. e-Pub 2003.
154. Gokhale S, Albarracin C, Arun B, Middleton L, Sahin A. Immunohistochemical expression of prostate specific antigen in normal breast tissue and breast neoplasms. Modern Pathology 16(1):29A, 2003. e-Pub 2003.
155. Lee P, Liu JS, Arun B, Sahin A. Expression of androgen receptor coactivator 70 in stage I and II invasive breast cancer 16(1):38A, 2003. e-Pub 2003.
156. Arun B, Kamal A, Middleton L, Wang X, Kau SW, Smith TL, Esteva F, Hortobagyi GN. Bcl-Expression predicts regional lymph node metastasis in early breast cancer. Proc Am Soc Oncol 22:862a, 2003. e-Pub 2003.
157. Arun B, Lammey J, Valero V, Babiera G, Cristofanilli M, Smith TL, Hortobagyi GN, Sneige N. Ductal lavage for short-term breast cancer chemoprevention trials. Proc AACR Frontiers in Cancer Prevention Research 2nd Annual International Conference, Phoenix, AZ, 2003. e-Pub 2003.
158. Cristofanilli M, Reuben JM, Fritsche HA, S-W K, Lara J, Arun B, Valero V, Chedid S, Doyle GV, Miller MC, Allard J, LWMM T, Hortobagyi GN. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. Proc Am Ass Can Res 44, 2003. e-Pub 2003.
159. Cristofanilli M, Khrisnamurthy S, Guerra L, Bisotooni K, Arun B, Walters R, Booser D, Coffee K, Valero V, Hortobagyi GN. Ad5CMV-p53 combined with Docetaxel (T) and Doxorubicin (D) as induction chemotherapy (IC) for patients with locally advanced breast cancer (LABC): preliminary report of safety and efficacy. Proc Am Soc Oncol 22:241b, 2003. e-Pub 2003.
160. Albarracin C, Arun B, Sahin A. Cell-Specific dysregulation of annex in I expression in breast cancer. Modern Pathology 16(1):21A, 2003. e-Pub 2003.
161. Sikov WM, Akerley W, Kahanic S, Mangalik A, Arun B, Houston GA, Perry MC, Bertoli L, Kugler J. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC). Proc Am Soc Oncol 21:34a, 2002. e-Pub 2002.
162. Arun B, Multani A, Rivera E, Valero V, Pusztai L, Rosales M, Cristofanilli M, Booser DJ, Hortobagyi GN, Pathak S. Telomeric DNA content is increased in blood of patients with breast cancer. Proc Am Soc Oncol 21:439a, 2002. e-Pub 2002.
163. Pusztai L, Mendoza TR, Reuben JM, Broemeling L, Lara J, Rivera E, Arun B, Esteva F, Valero V, Hortobagyi GN, Cleeland CS. Correlation between fatigue and musculoskeletal symptoms and chemotherapy-induced release of inflammatory cytokines in the blood. 2001 Annual SABCS Meeting 7, 2001. e-Pub 2001.
164. Rivera E, Arun B, Royce M, Adinin R, Valero V, Hoelzer K, Walters R, Wade III J, Pusztai L, Hortobagyi GN. Phase II study of Gemcitabine (G) and Doxil (D) combination chemotherapy in patients with metastatic breast cancer: preliminary results. 2001 Annual SABCS Meeting, 2001. e-Pub 2001.
165. Arun B, Yen C, Foster B, Gaynor R, Ashfaq R. Cyclooxygenase-2 expression in breast cancer and metastatic lymph node. Proc Am Soc Oncol 20:8b, 2001. e-Pub 2001.
166. Arun B, Zhang H, Mirza NQ, Hortobagyi GN, Hung M, Meric F. Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Research and Treatment 69(3):171a, 2001. e-Pub 2001.
167. Ashfaq R, Foster B, Kilic G, Cichon Y, Gaynor R, Arun B. Loss of FHIT expression in primary breast cancer correlates with p53 expression and inversely with Bcl-2 expression. Proc Am Soc Oncol 20:331b, 2001. e-Pub 2001.
168. Puzstai L, Neally K, Pallansch P, Rivera E, Arun B, Valero V, Cristofanilli M, Hortobagyi GN. Phase I-II study to evaluate safety and efficacy of Capecitabine (XELODA) and Exisulind (APOPTOSYN) combination therapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment 69(3):433a, 2001. e-Pub 2001.
169. Arun B, Yardley DA, Pusztai L, Gaynor R, Ashfaq R. Expression of bcl-2 and p53 in breast cancer and their metastatic lymph nodes. Proc Am Ass Cancer Res 42:220, 2001. e-Pub 2001.
170. Pusztai L, Symmans WF, Ayers M, Stec J, Clark E, Hess K, Sniege N, Esteva FJ, Arun B, Booser D, Rosales M, Hortobagyi GN. Correlation between gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer and clinicopathologic parameters. Clinical Cancer Research 7(11 Suppl. S):196, 2001. e-Pub 2001.
171. Ashfaq R, Yardley DA, Frankel EP, Arun B. Bcl-2 and p53 expression in breast cancer and their metastatic lymph nodes. Proc Am Soc Oncol 19:667a, 2000. e-Pub 2000.
172. Arun B, Cardillo M, Ozdemirli M, Kilic G. Human papilloma virus 18 E6 and E7 enhances irradiation-and chemotherapeutic agent induced apoptosis in P53 and RB mutated cervical cancer cell line. Proc Am Soc Oncol 17:562a, 1998. e-Pub 1998.
173. Arun B. Clinical Outcomes and the 21-Gene Recurrence Score Assay in Early-Stage Breast Cancer Associated with CHEK2, ATM and PALB2 Germline Pathogenic Variants. 2024 San Antonio Breast Cancer Symposium (SABCS).
174. Bevers TB, Sardesai S, Arun BK, Colditz GA, Fejerman L, Fisher C, Gandhi S, Goodwin HA, Gradishar WJ, Henderson K, Hendrix AA, Hwang S, Jacobs L, Jordan JA, King T, Kurian AW, Loftus LS, Master A, Merajver SD, Meszoely I, Moo TA, Mukhtar R, Parker CC, Proussaloglou EM, Rahimi A, Seewaldt V, Shah PD, Shubeck S, Specht MC, Wallace A, Wilke LG, Yellala A, Yung R, Bergman MA, Kumar R. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Risk Reduction. NCCN Annual 2025 Conference.

Book Chapters

1. Bayraktar S, Arun B. Epidemiology, Risk Factors and Prevention. In: Breast Cancer Diagnosis and Pathology. Springer, 57-87, 2016.
2. Ready K, Arun B. Breast cancer syndromes: Counseling and management. In: Advanced Therapy for Breast Cancer. B.C. Decker Inc. Publishers, 2011.
3. Arun B. Hereditary breast cancer risk and genetic counseling. In: ESGO Genetics. Springer, 1-6, 2011.
4. Arun B, Ready K. Genetic predisposition to breast cancer and genetic counseling and testing. In: Breast Cancer. 2nd. Springer, 57-82, 2007.
5. Arun B, Ready K. Hereditary breast cancer genetic predisposition to breast cancer [and genetic counseling and testing. In: Breast Cancer. Springer Science+Business Media, 2007.
6. Bottom K, O'Leary M, Sheaffer J, Phillips M, X-O S, Arun B. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival. In: Breast Cancer. National Cancer Institute, NIH Pub No. 06-5767, 111-121, 2006.
7. Arun B, Kuerer H. Breast cancer risk assessment and management. In: Breast Cancer. 2nd. B.C. Decker Inc. Publishers, 2005.
8. Arun B. Breast cancer risk assessment and management. In: Breast Cancer. 2nd. B.C. Decker Inc, 2005.
9. Arun B. Ductal lavage in risk reduction. In: Advanced Therapy of Breast Disease. 2nd. B.C. Decker Inc. Publishers, 113-119, 2004.
10. Arun B, Strong L. Breast cancer genetic syndromes. In: Advanced Therapy of Breast Disease. 2nd. B.C. Decker Inc. Publishers, 75-83, 2004.
11. Arun B, Hortobagyi GN. Chimioterapia adjuvant| Õi hormonoterapia cancerului mamar primar. Chapter 17. In: Tratamentul Conservator al Cancerului Mamar Incipient. Editura Universitar| Carol Davila, 275-295, 2003.
12. Arun B, Kessler CM. Clinical manifestations and therapy of the hemophilias. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th, 815-824, 2001.
13. Arun B, Philips M. Breast cancer in adolescents and young adults. In: AYA Monograph, 2000.
14. Bluebond R, Bannon SA, Hyde SM, Woodson AH, You NYQ, Lu KH, Arun B. Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling. In: Cancer Medicine. 10.